Black Widow Spider Envenomation

Injury MONDO:0800176 Pathograph 28 Show in embeddings browser Envenomation Arthropod Envenomation

Acute systemic envenomation following a bite by a widow spider (Latrodectus species). The syndrome is called latrodectism, and almost all of it is the work of a single 130 kDa protein toxin, alpha-latrotoxin, which is the only one of the venom's seven latrotoxins that targets vertebrates. The toxin does not block anything. It does the opposite of botulinum toxin: it drives presynaptic nerve terminals to discharge their neurotransmitter without regard to the normal controls on release, and the resulting cholinergic and adrenergic excess produces severe muscle cramping, autonomic hyperactivity and pain that is characteristically out of proportion to an almost unremarkable bite site. It is self-limited in the overwhelming majority of cases, which is what makes the evidence about how to treat it so contested.

Ask OpenScientist

Ask a research question about Black Widow Spider Envenomation. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

9
Pathophys.
16
Phenotypes
2
Hypotheses
2
Gaps
28
Pathograph
4
Medical Actions
1
Deep Research
◈

Mechanistic Hypotheses

2
Pore-mediated calcium influx drives the exocytosis
pore_mediated_calcium_influx CANONICAL
Evidence balance 1 support
The tetrameric toxin inserts into the presynaptic membrane and forms a cation-selective channel; calcium entering through that channel triggers the massive exocytosis. This is the structurally resolved account and the one the cryo-EM work describes in detail.
Pathograph links
Alpha-Latrotoxin Binding to Presynaptic Receptors -> Alpha-Latrotoxin Tetramer Insertion and Pore Formation DIRECT Receptor tethering raises the efficiency of membrane insertion by orders of magnitude; insertion is inefficient without it.
Alpha-Latrotoxin Tetramer Insertion and Pore Formation -> Presynaptic Calcium Influx DIRECT
Presynaptic Calcium Influx -> Unregulated Neurotransmitter Exocytosis DIRECT
Show evidence (1 reference)
PMID:10865131 SUPPORT REVIEW SYNTHESIS In Vitro
"The stimulation of secretion by alpha-latrotoxin in neuroendocrine cells is a consequence of Ca(2+) influx through these alpha-latrotoxin-induced channels."
States the canonical account - the channel is the route, and calcium influx through it is the trigger.
A receptor-signalling arm acts independently of the pore
receptor_mediated_secretion ALTERNATIVE
Evidence balance 6 support
A second route in which the toxin's receptors do more than tether it: engagement of latrophilin/CIRL, a G-protein-coupled receptor, stimulates secretion without requiring calcium entry through a pore. It began as an inference from a negative observation - exocytosis happens in the complete absence of extracellular calcium, which the pore account cannot explain - and has since been given a full cascade, demonstrated with a pore-deficient toxin mutant so that the pore cannot be doing the work. Recorded as ALTERNATIVE rather than CANONICAL because what has been demonstrated is spontaneous quantal release at the mouse neuromuscular junction; no work apportions the two arms in a human envenomation.
Pathograph links
Alpha-Latrotoxin Binding to Presynaptic Receptors -> Latrophilin Receptor Signalling at the Nerve Terminal DIRECT Under the alternative account the same binding event initiates receptor signalling rather than merely positioning the toxin.
Latrophilin Receptor Signalling at the Nerve Terminal -> Unregulated Neurotransmitter Exocytosis INDIRECT KNOWN INTERMEDIATES The intermediates are named: Gaq, phospholipase C, IP3, IP3-receptor store release, then store-operated calcium entry. INDIRECT rather than DIRECT because that is five steps, and KNOWN rather than UNKNOWN because each was tested rather than assumed.
Show evidence (6 references)
PMID:10382267 SUPPORT REVIEW SYNTHESIS In Vitro
"However, this mechanism fails to explain exocytosis which occurred in the complete absence of extracellular calcium."
The observation that requires a second arm at all, stated as the failure of the first. This is what makes the two accounts rival explanations rather than a single chain.
PMID:10865131 SUPPORT REVIEW SYNTHESIS In Vitro
"In addition to channel formation, alpha-latrotoxin enhances secretion in permeabilized cells through interaction with the plasma membrane receptor CIRL/latrophilin."
Secretion enhanced through the receptor in permeabilized cells, which is the pore-independent claim.
PMID:9430716 SUPPORT PRIMARY RESULT Model Organism
"The action of alpha-latrotoxin may therefore be mediated by independent parallel pathways, of which the CIRL/latrophilin pathway is sufficient for neurotransmitter release, whereas the neurexin I alpha pathway contributes to the Ca(2+)-dependent action of alpha-latrotoxin."
The strongest evidence for this hypothesis, and it is genetic rather than pharmacological: in neurexin-1alpha knockout mice the latrophilin pathway alone is sufficient for release. Note what this does and does not say - "independent parallel pathways" is about the two receptors, not about pore versus signalling, so it establishes that the latrophilin arm can carry the effect without establishing how.
+ 3 more references
?

Discussions and Knowledge Gaps

2
Does alpha-latrotoxin drive exocytosis through the pore it forms, through receptor signalling, or through both - and in what proportion in a human envenomation?
KNOWLEDGE GAP which_receptor_arm_carries_the_effect
Attached to
pathophysiology#Latrophilin Receptor Signalling at the Nerve Terminal mechanistic_hypotheses#receptor_mediated_secretion
Both arms are supported, and the evidence for each is of a different kind. Both arms are now mechanistically described, which is a change from how this was framed until recently. The pore's prepore and pore states are resolved by cryo-EM to 3.1 and 3.7 Angstrom respectively, and the channel's conductance is measured. The receptor arm has its own delineated cascade - latrophilin-1 to Gaq-phospholipase C to IP3 to store release to store-operated calcium entry - established with a pore-deficient toxin mutant in latrophilin-1 knockout mice, which is the cleanest available way to isolate it from the pore. What remains open is not whether either arm exists but what each contributes in a human envenomation. The receptor cascade was characterised for spontaneous quantal release at the mouse neuromuscular junction, not for the massive discharge of latrodectism; all of the discriminating work is in cultured cells, synaptosomes and mice; and nothing in the clinical picture distinguishes the two.
Show evidence (1 reference)
PMID:10382267 SUPPORT REVIEW SYNTHESIS In Vitro
"The molecular details of how alpha-latrotoxin binding is transduced eventually to exocytosis remain to be elucidated."
The gap, stated by the review that lays out both receptor families.
Does equine antivenom add anything to adequate analgesia in latrodectism, and if the two placebo-controlled trials really disagree, why?
KNOWLEDGE GAP antivenom_efficacy_is_unsettled
Attached to
treatments#Equine antivenom
RAVE-II randomised 224 patients against placebo on top of standardised analgesia and found no significant benefit. Dart and colleagues randomised 60 patients against placebo and met their primary endpoint. Four candidate explanations remain, and the entry cannot choose between them: a different spider and a different antivenom product (Latrodectus hasselti in Australia versus L. mactans in the United States - the products' antibody formats are not described in either trial abstract, so no comparison of them is asserted here); a different primary endpoint (pain improvement at 2 hours versus sustained reduction over 48 hours); a fourfold difference in size, with RAVE-II's confidence interval only just crossing zero; and the fact that RAVE-II gave both arms standardised analgesia first, which is a harder comparator to beat. The species explanation is the weakest of the four: redback antivenom neutralises L. mactans venom in a mouse model, so the two products are not obviously aimed at incomparable targets. The practical question - whether to give a product that causes systemic hypersensitivity in about 1 in 28 recipients, and that killed a patient in the largest published series - turns on the answer.
Show evidence (2 references)
PMID:24999282 SUPPORT BACKGROUND Human Clinical
"There remains considerable controversy over antivenom treatment."
The trialists' own framing of the question, written before they added the largest negative result to it.
PMID:11407496 SUPPORT PRIMARY RESULT Model Organism
"Redback spider antivenom is effective in neutralizing the lethal effects of L. hesperus and L. mactans venoms in a mouse envenomation model."
Bears directly on the species explanation, and against it: the Australian antivenom neutralises both American species' venom in a mouse model, so species difference alone is a weak account of why the two trials disagree. The species names are the point of the quote, which is why the whole sentence is given.
⚙

Pathophysiology

9
Alpha-Latrotoxin Binding to Presynaptic Receptors
Alpha-latrotoxin binds two structurally unrelated families of presynaptic receptor - neurexin-1alpha, which binds calcium-dependently, and latrophilin/CIRL, a G-protein-coupled receptor that binds without calcium. Their shared and best-evidenced function is tethering: holding the toxin at the membrane so that it can insert. The evidence for that is unusually clean, because a chimera carrying only the extracellular domain of CIRL-1 on an unrelated viral transmembrane anchor produced the same channels as the wild-type receptor.
A receptor-signalling arm acts independently of the pore Pore-mediated calcium influx drives the exocytosis
motor neuron CL:0000100 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves motor neuron (CL:0000100). CL:0000100 is a cell type from the Cell Ontology. autonomic and neurosecretory neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves autonomic and neurosecretory neuron, annotated with neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Alpha-Latrotoxin Tetramer Insertion and Pore Formation Receptor tethering raises the efficiency of membrane insertion by orders of magnitude; insertion is inefficient without it. Pore-mediated calcium influx drives the exocytosis
Latrophilin Receptor Signalling at the Nerve Terminal Under the alternative account the same binding event initiates receptor signalling rather than merely positioning the toxin. A receptor-signalling arm acts independently of the pore
Pain Pain begins where the venom is deposited, so it is drawn from the first node rather than from the systemic ones. Unknown intermediates on purpose: the entry models no local sensory-terminal node, and no cited source traces the route from toxin binding to nociception.
Show evidence (3 references)
PMID:39362850 SUPPORT BACKGROUND In Vitro
"This 130 kDa toxin binds to receptors at presynaptic nerve terminals and triggers a massive release of neurotransmitters."
The target and the outcome in one sentence. BACKGROUND because it is the structural paper's framing of established biology rather than its own cryo-EM result.
PMID:9430716 SUPPORT BACKGROUND In Vitro
"A surprising finding was the biochemical description of two distinct cell surface proteins that bind alpha-latrotoxin with nanomolar affinities; Neurexin I alpha binds alpha-latrotoxin in a Ca(2+)-dependent manner, and CIRL/latrophilin binds in a Ca(2+)-independent manner."
Both receptor families and the binding property that distinguishes them, which is the claim this node makes.
PMID:10382267 SUPPORT REVIEW SYNTHESIS In Vitro
"Neurexins are single transmembrane proteins which bind to alpha-latrotoxin in a calcium-dependent manner and also interact with the synaptic vesicle protein, synaptotagmin. On the other hand, latrophilin is a seven-transmembrane protein and belongs to the family of G-protein-coupled receptors."
The two receptor families and the property that distinguishes them, which is why the calcium-free experiments discriminate between the hypotheses.
Alpha-Latrotoxin Tetramer Insertion and Pore Formation
In the presence of calcium or magnesium the toxin assembles into a C4-symmetric tetramer, then undergoes a large conformational change: four N-terminal helical bundles refold into a rigid coiled-coil stalk that drives a pair of helices into the bilayer, opening a cation-permeable channel. The prepore and pore states have both been resolved by cryo-EM, so this is a structurally described event rather than an inferred one.
Pore-mediated calcium influx drives the exocytosis
cation-selective channel formed by an exogenous toxin GO:0005261 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves cation-selective channel formed by an exogenous toxin, annotated with monoatomic cation channel activity (GO:0005261), qualified as gain of function. GO:0005261 is a molecular function from the Gene Ontology. ⇑ GAIN OF FUNCTION toxin activity of alpha-latrotoxin GO:0090729 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves toxin activity of alpha-latrotoxin, annotated with toxin activity (GO:0090729). GO:0090729 is a molecular function from the Gene Ontology.
Downstream
Presynaptic Calcium Influx Pore-mediated calcium influx drives the exocytosis
Show evidence (3 references)
PMID:10625427 SUPPORT PRIMARY RESULT In Vitro
"We discovered that alpha-latrotoxin exists in two oligomeric forms: it is dimeric in EDTA but forms tetramers in the presence of Ca2+ or Mg2+."
The divalent-cation dependence of tetramerization, which is the first step of this node.
PMID:10625427 SUPPORT PRIMARY RESULT In Vitro
"The C4-symmetric tetramers represent the active form of alpha-latrotoxin; they have an axial channel and can insert into lipid bilayers with their hydrophobic base, providing the first model of alpha-latrotoxin pore formation."
The tetramer as the active, membrane-inserting form.
PMID:39362850 SUPPORT PRIMARY RESULT In Vitro
"Four distinct helical bundles rearrange and together form a highly stable, 15 nm long, cation-impermeable coiled-coil stalk. This stalk, in turn, positions an N-terminal pair of helices within the membrane, thereby enabling the assembly of a cation-permeable channel."
The prepore-to-pore transition in structural detail, and the source of the two resolutions quoted elsewhere in this entry.
Latrophilin Receptor Signalling at the Nerve Terminal
The alternative arm, and no longer a black box. Engagement of latrophilin-1 couples to Gaq and phospholipase C, generating IP3 that releases calcium from intracellular stores through IP3 receptors; the resulting store depletion opens store-operated calcium entry, which supplies the sustained calcium that exocytosis needs. The cascade was delineated at the mouse neuromuscular junction using a pore-deficient toxin mutant, so the pore is excluded by construction rather than by argument. What this does not establish is how much of a human envenomation runs through it.
A receptor-signalling arm acts independently of the pore
G protein-coupled receptor signaling pathway GO:0007186 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased G protein-coupled receptor signaling pathway (GO:0007186). GO:0007186 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Unregulated Neurotransmitter Exocytosis The intermediates are named: Gaq, phospholipase C, IP3, IP3-receptor store release, then store-operated calcium entry. INDIRECT rather than DIRECT because that is five steps, and KNOWN rather than UNKNOWN because each was tested rather than assumed. A receptor-signalling arm acts independently of the pore
Show evidence (1 reference)
PMID:10692492 REFUTE PRIMARY RESULT In Vitro
"An analysis of CIRL-1 mutants indicated that channel formation in HEK293 cells is unlikely to be transduced by a G-protein-dependent mechanism."
REFUTE, and narrowly: what it excludes is a G-protein-dependent route to *channel formation*, in HEK293 cells overexpressing CIRL-1. This node claims a G-protein route to *secretion*, which is a different claim in a different system, and PMID:42121922 has since demonstrated exactly that route at the neuromuscular junction. Kept because it is a real negative result about a neighbouring claim and a reader should see it; it is not evidence that this arm does not exist.
Presynaptic Calcium Influx
Calcium enters the terminal through the toxin's own channel, a high conductance pore measured at around 400 pS, bypassing the voltage-gated calcium channels that normally gate release.
Pore-mediated calcium influx drives the exocytosis
calcium ion transmembrane transport GO:0070588 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased calcium ion transmembrane transport (GO:0070588). GO:0070588 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Unregulated Neurotransmitter Exocytosis Pore-mediated calcium influx drives the exocytosis
Show evidence (2 references)
PMID:10692492 SUPPORT PRIMARY RESULT In Vitro
"we demonstrate that the interaction of alpha-latrotoxin with CIRL-1 produces a high conductance channel that permits increases in cytosolic Ca(2+)"
States what this node claims - the channel admits calcium into the cytosol - rather than only reporting a conductance.
PMID:10692492 SUPPORT INDIRECT PRIMARY RESULT In Vitro
"alpha-Latrotoxin interaction with CIRL-1 transiently expressed in bovine chromaffin cells produced a 400-pS channel, which rarely closed under Ca(2+)-free conditions."
The measured conductance. INDIRECT because it was measured in CIRL-1-overexpressing bovine chromaffin cells, not at a presynaptic terminal, which is what this node is about.
Unregulated Neurotransmitter Exocytosis
The convergence point of both hypothesis arms, and the event that produces the whole clinical syndrome. Vesicular acetylcholine and catecholamines are discharged continuously rather than in response to action potentials.
synaptic vesicle exocytosis GO:0016079 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased synaptic vesicle exocytosis (GO:0016079). GO:0016079 is a biological process from the Gene Ontology. ↑ INCREASED neurotransmitter secretion GO:0007269 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neurotransmitter secretion (GO:0007269). GO:0007269 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Synaptic Vesicle Pool Depletion
Sustained Motor End-Plate Activation
Autonomic Neurotransmitter Excess
Show evidence (1 reference)
PMID:10382267 SUPPORT REVIEW SYNTHESIS In Vitro
"The major component of black widow spider venom, alpha-latrotoxin, triggers massive exocytosis in a variety of neurosecretory cells."
The node's central claim, and that it is not restricted to one cell type.
Synaptic Vesicle Pool Depletion
Sustained exocytosis outrunning endocytic retrieval empties the terminal of both transmitter quanta and the vesicles themselves, with vesicle membrane left incorporated into the axolemma. Read the limitation, because it is load-bearing: the experiment showing this was run in the *absence* of extracellular calcium, and the same paper's calcium-present control found active recycling of both quanta and vesicles with no depletion at all. Calcium is present in an envenomated patient, so this node describes a demonstrated capability of the toxin rather than an established step of the human syndrome. No source cited here establishes that vesicle depletion is what makes latrodectism self-limited.
motor neuron CL:0000100 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves motor neuron (CL:0000100). CL:0000100 is a cell type from the Cell Ontology.
Show evidence (2 references)
PMID:1967610 SUPPORT INDIRECT PRIMARY RESULT In Vitro
"In nerve-muscle preparations treated for 1 h with a low dose of alpha-latrotoxin in the absence of extracellular Ca2+ (a condition under which nerve terminals are depleted of both quanta of neurotransmitter and synaptic vesicles), the immunolabeling for both proteins was distributed along the axolemma."
Depletion of both quanta and vesicles, with vesicle membrane proteins redistributed to the axolemma. INDIRECT because the condition is calcium-free and an envenomated patient is not - see the refuting item below, which is the same paper's own control.
PMID:1967610 REFUTE PRIMARY RESULT In Vitro
"When the same dose of alpha-latrotoxin was applied in the presence of extracellular Ca2+, the immunoreactivity patterns resembled those obtained in resting preparations"
The same paper's calcium-present control, which is the condition that applies in a patient, and in which retrieval kept pace. REFUTE against reading this node as an established step of the human syndrome. Recorded rather than omitted because the supporting quote alone would misrepresent the paper.
Sustained Motor End-Plate Activation
Continuous acetylcholine release at the neuromuscular junction holds skeletal muscle in involuntary contraction. The cramping spreads contiguously from the bitten limb to the trunk, which is the feature that most often distinguishes latrodectism from an acute abdomen at the bedside.
Downstream
Muscle spasm
Rigidity
Abdominal pain
Rhabdomyolysis
Blepharospasm The muscular component of facies latrodectismica - sustained orbicularis oculi contraction, the same end-plate mechanism as the cramping elsewhere.
Show evidence (1 reference)
PMID:29133072 SUPPORT BACKGROUND Human Clinical
"Black widow species (Latrodectus species) envenomation can produce a syndrome characterized by painful muscle rigidity and autonomic disturbances."
The two clinical arms this node and the next one split into. BACKGROUND because it is the study's framing rather than its own result.
Autonomic Neurotransmitter Excess
The same unregulated release at autonomic terminals - acetylcholine at ganglia and exocrine glands, catecholamines at postganglionic sympathetic terminals - produces a mixed autonomic picture rather than a purely sympathetic one. Hypertension, tachycardia and diaphoresis sit alongside nausea, vomiting and lacrimation.
Downstream
Hypertension
Tachycardia
Hyperhidrosis
Nausea
Vomiting
Epiphora Cholinergic drive at the lacrimal gland, the same exocrine mechanism as the salivation and bronchial secretion described for autonomic excess.
Periorbital edema Part of facies latrodectismica. Drawn with unknown intermediates because the source describes the sign without establishing what produces the oedema; a local autonomic vasomotor effect is the usual explanation and is not demonstrated.
Envenomation-Associated Myocardial Injury
Show evidence (2 references)
PMID:25978056 SUPPORT REVIEW SYNTHESIS Human Clinical
"The widow venom, a powerful neurotoxin known as a-latrotoxin, causes muscle pain, diaphoresis, tachycardia, flushing, and hypertension."
Names four of the autonomic features wired downstream of this node, and attributes them to the toxin rather than to pain alone.
PMID:21762981 SUPPORT REVIEW SYNTHESIS Human Clinical
"Latrodectism results from bites by widow spiders (Latrodectus spp) and causes local, regional, or generalised pain associated with non-specific symptoms and autonomic effects."
The authoritative review's statement of the syndrome, including its autonomic component.
Envenomation-Associated Myocardial Injury
A rare complication: myocarditis with raised troponin and, in reported cases, echocardiographic abnormality. Deliberately named for the association rather than for a mechanism - a catecholamine-mediated route is the usual explanation and is plausible given the adrenergic excess upstream, but no source cited here demonstrates it, so the node does not assert it. Curated because it is the one route by which a self-limited envenomation becomes an intensive care problem.
heart UBERON:0000948 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart (UBERON:0000948). UBERON:0000948 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Myocarditis
Show evidence (1 reference)
PMID:34027976 SUPPORT BACKGROUND Human Clinical
"Latrodectism is a severe systemic manifestation of the envenomation that includes severe abdominal pain mimicking acute surgical abdomen and, in rare cases, could lead to acute myocarditis and rhabdomyolysis."
Places myocarditis and rhabdomyolysis as rare complications of the systemic syndrome, which is what this node and the rhabdomyolysis edge above assert.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Black Widow Spider Envenomation Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Cardiovascular 4
Hypertension HP:0000822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertension (HP:0000822). HP:0000822 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25978056 SUPPORT REVIEW SYNTHESIS Human Clinical
"causes muscle pain, diaphoresis, tachycardia, flushing, and hypertension"
Hypertension named among the toxin's autonomic effects.
Tachycardia HP:0001649 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tachycardia (HP:0001649). HP:0001649 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31492593 SUPPORT BACKGROUND Human Clinical
"autonomic disturbances, such as tachycardia, hypertension, and diaphoresis"
Tachycardia named among the characteristic autonomic disturbances.
Myocarditis HP:0012819 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myocarditis (HP:0012819). HP:0012819 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34027976 SUPPORT PRIMARY RESULT Human Clinical
"We report the case of a 26-year-old active duty male soldier evacuated from field training with latrodectism and possible envenomation-induced myocarditis after a suspected BWS bite."
The reported case of envenomation-associated myocarditis this phenotype records.
PMID:32462634 SUPPORT BACKGROUND Human Clinical
"Cases of myocarditis following a BWS bite are rare but they can be fatal on occasion."
The correction to any impression that this complication is uniformly reversible. Cited specifically so the description cannot be read as reassurance.
Erythema HP:0010783 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Erythema at the bite site, annotated with Erythema (HP:0010783). HP:0010783 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37377825 SUPPORT PRIMARY RESULT Human Clinical
"Physical examination revealed a 3 × 2 mm area of erythema at the bite site, board-like abdominal rigidity and hyperactive stretch reflexes."
A measured bite-site finding in a confirmed widow envenomation, and the scale is the point - three millimetres by two. No frequency is recorded because this is one case.
Digestive 2
Nausea HP:0002018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nausea (HP:0002018). HP:0002018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37377825 SUPPORT BACKGROUND Human Clinical
"The effects of BWS bites ranges from local damage to systemic manifestations including paresthesia, stiffness, abdominal cramps, nausea, vomiting, headache, anxiety, hypertension and tachycardia."
Names nausea among the systemic manifestations. BACKGROUND because it is the case report's framing of the syndrome rather than its own finding.
Vomiting HP:0002013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vomiting (HP:0002013). HP:0002013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37377825 SUPPORT BACKGROUND Human Clinical
"The effects of BWS bites ranges from local damage to systemic manifestations including paresthesia, stiffness, abdominal cramps, nausea, vomiting, headache, anxiety, hypertension and tachycardia."
Names vomiting among the systemic manifestations.
Eye 1
Epiphora HP:0009926 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lacrimation, annotated with Epiphora (HP:0009926). HP:0009926 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31492593 SUPPORT BACKGROUND Human Clinical
"characterized by periorbital edema, lacrimation, and blepharospasm"
Names lacrimation as the third component of the sign.
Head and Neck 2
Periorbital edema HP:0100539 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Periorbital edema (HP:0100539). HP:0100539 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31492593 SUPPORT BACKGROUND Human Clinical
""Latrodectus facies" or "facies latrodectismica" is an additional distinctive but rarely described clinical finding characterized by periorbital edema, lacrimation, and blepharospasm."
Defines the sign and names periorbital oedema as one of its three components.
Blepharospasm HP:0000643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Blepharospasm (HP:0000643). HP:0000643 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31492593 SUPPORT BACKGROUND Human Clinical
"characterized by periorbital edema, lacrimation, and blepharospasm"
Names blepharospasm as a component of the sign.
Integument 1
Hyperhidrosis HP:0000975 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diaphoresis, annotated with Hyperhidrosis (HP:0000975). HP:0000975 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31492593 SUPPORT BACKGROUND Human Clinical
"autonomic disturbances, such as tachycardia, hypertension, and diaphoresis"
Diaphoresis named among the characteristic autonomic disturbances.
Metabolism 1
Local edema HP:0000969 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Edema at the bite site, annotated with Edema (HP:0000969). HP:0000969 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32462634 SUPPORT BACKGROUND Human Clinical
"Patients may experience edema, necrosis, and bacterial superinfection at the inoculum site."
A widow case report's own framing of the local findings. Quoted whole rather than trimmed to the edema: the same sentence also claims necrosis at the bite, which no other source cited here reports and which is the classic loxoscelism finding, so the clause is left visible rather than cropped away. Only the edema is curated as a phenotype.
Musculoskeletal 3
Muscle spasm HP:0003394 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle cramping, annotated with Muscle spasm (HP:0003394). HP:0003394 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22058673 SUPPORT BACKGROUND Human Clinical
"Black widow spider bites cause a characteristic envenomation syndrome consisting of severe pain, muscle cramping, abdominal pain, and back pain."
Names cramping as a defining component of the syndrome.
Rigidity HP:0002063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle rigidity, annotated with Rigidity (HP:0002063). HP:0002063 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29133072 SUPPORT BACKGROUND Human Clinical
"envenomation can produce a syndrome characterized by painful muscle rigidity and autonomic disturbances"
Rigidity named as a defining feature of the syndrome.
Rhabdomyolysis HP:0003201 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rhabdomyolysis (HP:0003201). HP:0003201 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35435990 SUPPORT BACKGROUND Human Clinical
"Rhabdomyolysis after spider bite has been reported in a small number of patients, and myocarditis in even fewer."
Establishes both the occurrence and the rarity, which is what this phenotype's description claims.
Constitutional 2
Abdominal pain HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34027976 SUPPORT BACKGROUND Human Clinical
"severe abdominal pain mimicking acute surgical abdomen"
The clinical mimicry that makes this phenotype diagnostically important.
Pain HP:0012531 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pain at and spreading from the bite site, annotated with Pain (HP:0012531). HP:0012531 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:21762981 SUPPORT REVIEW SYNTHESIS Human Clinical
"Latrodectism results from bites by widow spiders (Latrodectus spp) and causes local, regional, or generalised pain associated with non-specific symptoms and autonomic effects."
Names the local-to-regional-to-generalised progression, attributed to Latrodectus specifically rather than to spider bite in general.
💊

Medical Actions

4
Opioid analgesia
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: morphine CHEBI:17303 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses morphine (CHEBI:17303). CHEBI:17303 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
The mainstay, and the comparator RAVE-II measured antivenom against. Pain in latrodectism is characteristically refractory to simple analgesics, so intravenous opioids are the practical first line.
Mechanism Target:
MODULATES Sustained Motor End-Plate Activation — Drawn at the node that generates the pain rather than upstream, and MODULATES rather than INHIBITS on purpose - opioids do nothing to the toxin or to transmitter release, they raise the threshold at which the resulting nociception is felt.
Show evidence (1 reference)
PMID:1351707 SUPPORT INDIRECT PRIMARY RESULT Human Clinical
"Fifty-five percent of patients initially receiving IV morphine and 70% of those initially receiving both IV morphine and benzodiazepines obtained symptomatic relief without additional medication."
INDIRECT: a therapeutic response cited in support of the node it acts on. The series is retrospective and uncontrolled, so the numbers describe practice rather than isolating the drug's effect.
Show evidence (1 reference)
PMID:22058673 SUPPORT BACKGROUND Human Clinical
"The significant pain associated with envenomation is often refractory to traditional analgesics."
Why opioids rather than simple analgesia, stated as the clinical problem.
Benzodiazepine muscle relaxation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: diazepam CHEBI:49575 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses diazepam (CHEBI:49575). CHEBI:49575 is a therapeutic agent from Chemical Entities of Biological Interest. benzodiazepine NCIT:C1012 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses benzodiazepine (NCIT:C1012). NCIT:C1012 is a therapeutic agent from the NCI Thesaurus.
Platform: Small molecule
Given with opioids rather than instead of them. In the largest published series the combination outperformed opioid alone, and benzodiazepines are the second most frequently recorded therapy in US poison centre data.
Mechanism Target:
MODULATES Sustained Motor End-Plate Activation — Central muscle relaxation against the sustained contraction this node produces.
Show evidence (1 reference)
PMID:1351707 SUPPORT INDIRECT PRIMARY RESULT Human Clinical
"Fifty-five percent of patients initially receiving IV morphine and 70% of those initially receiving both IV morphine and benzodiazepines obtained symptomatic relief without additional medication."
The same sentence supports both drugs, and the comparison within it - 70% versus 55% - is what justifies adding the benzodiazepine. INDIRECT, and uncontrolled.
Show evidence (1 reference)
PMID:39670790 SUPPORT PRIMARY RESULT Human Clinical
"The most common therapies received were wound care (43.7%) and benzodiazepines (18.6%)."
Benzodiazepines at 18.6%, second only to wound care. The abstract does not report opioid use, so this establishes frequency in practice rather than that benzodiazepines are the commonest drug given.
Equine antivenom
Action: antivenom administrationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antivenom administration, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Platform: Other
The contested treatment. Four studies bear on it and they do not agree, which is curated here rather than resolved: a large retrospective series reporting resolution in about half an hour, a route-comparison trial whose authors concluded antivenom may add nothing over placebo, a placebo-controlled trial in 224 patients finding no benefit over standardised analgesia, and a second placebo-controlled trial in 60 patients meeting its primary endpoint. The entry records all four and the reasons they may differ.
Mechanism Target:
INHIBITS Alpha-Latrotoxin Binding to Presynaptic Receptors — Antivenom neutralises circulating toxin, so it acts upstream of the receptor - which is also the likeliest reason the trials disagree. By the time a patient presents in severe pain the binding and insertion steps have already happened, and neutralising toxin that has not yet bound cannot undo them.
Show evidence (2 references)
PMID:11407496 SUPPORT INDIRECT PRIMARY RESULT Model Organism
"Redback spider antivenom is effective in neutralizing the lethal effects of L. hesperus and L. mactans venoms in a mouse envenomation model."
Neutralisation is the mechanism this edge asserts. INDIRECT because it is a mouse lethality assay rather than a measurement at the receptor and the antigen was premixed with antibody, which is the condition the companion item below records.
PMID:11407496 SUPPORT PRIMARY RESULT Model Organism
"While this study is limited by the optimized premixing of antigen with antibody"
The authors' own caveat, and it is the same point this edge makes: premixing guarantees the antivenom meets the toxin before the toxin meets a receptor, which is exactly the condition a patient presenting hours after a bite does not satisfy. Quoted because it strengthens the edge's stated limitation rather than the treatment's case.
Show evidence (9 references)
PMID:1351707 SUPPORT INDIRECT PRIMARY RESULT Human Clinical
"Fifty-eight patients received antivenin with complete resolution of symptoms in a mean time of 31 +/- 26.7 minutes."
The positive retrospective signal, and the one clinicians most often cite. INDIRECT and uncontrolled - there is no comparator arm inside this number, and a self-limited syndrome will resolve on its own.
PMID:24999282 REFUTE PRIMARY RESULT Human Clinical
"The addition of antivenom to standardized analgesia in patients with latrodectism did not significantly improve pain or systemic effects."
The largest placebo-controlled trial, and it is negative. REFUTE against the claim that antivenom adds benefit on top of adequate analgesia - which is the claim that matters clinically, since analgesia is given either way.
PMID:24999282 REFUTE PRIMARY RESULT Human Clinical
"Two hours after treatment, 26 of 112 patients (23%) from the placebo arm had a clinically significant improvement in pain versus 38 of 112 (34%) from the antivenom arm (difference in favor of antivenom 10.7%; 95% confidence interval -1.1% to 22.6%; P=.10)."
The numbers behind that conclusion. Worth reading rather than summarising: the point estimate favours antivenom by 10.7 points and the interval only just crosses zero, so this is an underpowered null as much as a demonstration of no effect.
+ 6 more references
Calcium gluconate
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: calcium gluconate CHEBI:3309 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses calcium gluconate (CHEBI:3309). CHEBI:3309 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Historical, and recorded because it was standard practice rather than despite it. Intravenous calcium was for years the recommended first-line treatment for severe envenomation; the largest series tested it against opioids and found it did not work.
Show evidence (2 references)
PMID:1351707 REFUTE PRIMARY RESULT Human Clinical
"Calcium gluconate was not effective in providing symptomatic relief in this series, with 96% of the grade 2 and 3 envenomations treated initially with calcium gluconate requiring the addition of IV opioids or other analgesics for symptomatic relief."
REFUTE, and quantified: 96% of patients given calcium first needed something else anyway. No target_mechanisms edge is drawn, because on this evidence it does not act on the pathograph at all.
PMID:1351707 REFUTE PRIMARY RESULT Human Clinical
"Although calcium gluconate usually has been considered the first-line treatment of severe envenomations by black widow spiders, we found it ineffective for pain relief compared with a combination of IV opioids and benzodiazepines."
States both the former standard and the finding against it, which is why this treatment is curated rather than omitted.
🌍

Environmental Factors

1
Bite by a female widow spider
exposure to alpha-latrotoxin by spider bite ECTO:0000730 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to alpha-latrotoxin by spider bite, annotated with exposure to neurotoxin (ECTO:0000730). ECTO:0000730 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Bound to the generic `ECTO:0000730` because ECTO has no spider, venom, bite or arthropod exposure class. OLS `q=venom, ontology=ecto` returns only CHEBI and FOODON hits (`CHEBI:78505` venom, `CHEBI:30751` formic acid, `CHEBI:6736` melittin); `q=spider, ontology=ecto` returns `CHEBI:6651` malathion and `FOODON:03414899` terrestrial invertebrate; `q=bite, ontology=ecto` returns `CHEBI:78505` venom, `ExO:0000060` injection route and `GO:0071626` mastication; `q=arthropod, ontology=ecto` returns UBERON, NCBITaxon and CHEBI terms only. None is an exposure class.
The exposure is an injection through the chelicerae into subcutaneous tissue. Only the mature female is capable of clinically significant envenomation. Bites are domestic and occupational rather than exotic - woodpiles, outbuildings, stored furniture - and cluster in warm months and warm states.
Show evidence (1 reference)
PMID:39670790 SUPPORT PRIMARY RESULT Human Clinical
"Exposures occurred with higher frequency in warm-weather states and during summer months."
The geographic and seasonal distribution of the exposure, across 15,299 reported cases.
Mechanism Target:
TRIGGERS Alpha-Latrotoxin Binding to Presynaptic Receptors — The bite is the route by which the toxin reaches presynaptic terminals; nothing in the chain happens without it.
Show evidence (1 reference)
PMID:39670790 SUPPORT BACKGROUND Human Clinical
"The black widow spider, Latrodectus mactans, stands out as one of the most medically significant arachnids due to its extensive geographic distribution in the United States and its ability to produce a potent neurotoxin, α-latrotoxin."
Names the exposure and the toxin it delivers, which is what this link asserts.
🔬

Biochemical Markers

1
Creatine kinase (INCREASED)
Pathograph Readouts
Readout Of Rhabdomyolysis Positive Monitoring
CK release reports the muscle injury, and is the reason the complication is looked for rather than waited for.
Show evidence (1 reference)
PMID:35435990 SUPPORT BACKGROUND Human Clinical
"These patients should be evaluated for arrhythmia, rhabdomyolysis and myocarditis."
The authors' recommendation that this is monitored for, which is the use context this readout records.
Show evidence (1 reference)
PMID:35435990 SUPPORT PRIMARY RESULT Human Clinical
"In laboratory tests, creatine kinase was elevated."
The measurement itself, in the reported case of envenomation with rhabdomyolysis.
📊

Prevalence

1
United States
Annual Incidence Not yet documented
Recorded as a reported-exposure count rather than a rate. 15,299 exposures reported to US poison centres over 11 years is roughly 1,400 a year, but poison-centre reports are voluntary and capture only the fraction that prompts a call, so no per-100,000 figure can be derived from it honestly.
Show evidence (1 reference)
PMID:39670790 SUPPORT PRIMARY RESULT Human Clinical
"During the studied period, a total of 15,299 cases of Latrodectus spp exposures were reported to US poison centers."
The exposure count and its source, over a defined 11-year window.
⚖️

Clinical Burden

Variable
Most exposures are minor and managed without a healthcare visit at all, but a minority produce pain severe enough to require intravenous opioids, and a small number produce myocarditis or rhabdomyolysis. VARIABLE rather than LOW because the distribution is genuinely wide and symptoms are more severe in young children; VARIABLE rather than MODERATE because the modal case is minor. Deaths from the envenomation itself are not reported in the sources cited here - but the largest series records a death from the antivenom, which is a different claim and is curated on that treatment.
Show evidence (3 references)
PMID:39670790 SUPPORT PRIMARY RESULT Human Clinical
"Poison center data indicate that most black widow spider exposures result in minor consequences."
The low-burden end of the distribution, across 15,299 reported exposures.
PMID:39670790 SUPPORT PRIMARY RESULT Human Clinical
"Hospital admission was required for 10.0% of exposures."
The other end, and the reason the level is not LOW - one in ten reported exposures is admitted.
PMID:29133072 SUPPORT BACKGROUND Human Clinical
"Symptoms tend to be more severe in young children and adults."
The age dependence this rationale invokes, which would otherwise be uncited.
{ }

Source YAML

click to show 
name: Black Widow Spider Envenomation
creation_date: '2026-09-18T17:30:00Z'
category: Injury
description: >-
  Acute systemic envenomation following a bite by a widow spider (Latrodectus
  species). The syndrome is called latrodectism, and almost all of it is the
  work of a single 130 kDa protein toxin, alpha-latrotoxin, which is the only
  one of the venom's seven latrotoxins that targets vertebrates. The toxin does
  not block anything. It does the opposite of botulinum toxin: it drives
  presynaptic nerve terminals to discharge their neurotransmitter without
  regard to the normal controls on release, and the resulting cholinergic and
  adrenergic excess produces severe muscle cramping, autonomic hyperactivity
  and pain that is characteristically out of proportion to an almost
  unremarkable bite site. It is self-limited in the overwhelming majority of
  cases, which is what makes the evidence about how to treat it so contested.
notes: >-
  No GeneReviews chapter exists and none is expected: this is an acquired
  envenomation with no Mendelian basis, so `just check-genereviews` returns
  NO_CHAPTER for both Bookshelf collections. There is likewise no `genetic:`
  section. The host proteins that matter here - neurexin-1alpha and
  latrophilin-1/ADGRL1 - are the toxin's receptors, not disease genes, and no
  human susceptibility locus has been established; they are curated as
  mechanism rather than as genetics.

  Two scope exclusions, recorded as decisions. **The insect- and
  crustacean-specific latrotoxins are not modelled.** Widow venom contains five
  latroinsectotoxins and one latrocrustatoxin alongside alpha-latrotoxin; they
  are irrelevant to human envenomation and appear here only in the sentence
  establishing that alpha-latrotoxin is the vertebrate-active one. **The local
  bite lesion is modelled only as far as the sources support.** No
  tissue-destruction branch is curated: the necrotic-arachnidism picture
  belongs to Loxosceles, and nothing cited here describes tissue destruction
  in a widow bite in enough detail to model one. The single source that
  mentions necrosis at all, `PMID:32462634`, does so in one framing sentence,
  which is quoted whole under the local oedema phenotype rather than cropped
  to the convenient half - so the claim is visible rather than hidden, and
  only the oedema is curated from it. Three local bite-site phenotypes are
  curated: erythema, local pain and local oedema. The target-pattern
  localized sweating is not, because no source cited here describes it in a
  quotable sentence about a widow bite. The frequencies circulating for the
  local findings are not curated either - they come from an uncited table in
  the deep-research report rather than from a paper, so each phenotype is
  cited to a source that states the finding instead. Note also that the
  obvious erythema sentence in `PMID:21762981` is about *loxoscelism* -
  Loxosceles, not Latrodectus - so it cannot be cited here, which is the
  ordinary
  wrong-disease trap in a review that covers several spiders at once.

  **No module conformance is declared, and that is a decision rather than an
  omission.** The two candidate modules both model the wrong direction.
  `neuromuscular_transmission_failure` is organised around loss of the safety
  factor of neuromuscular transmission - reduced quantal release - which is
  what botulinum toxin does and is the precise inverse of what
  alpha-latrotoxin does. `synaptic_vesicle_cycle` names every one of its nodes
  for an impairment or deficiency of the release machinery. Latrodectism is
  pathological *excess* of release by an intact machine driven by an exogenous
  toxin, so conforming to either would assert the opposite of the mechanism
  this entry curates. A module for toxin-driven unregulated exocytosis would be
  a new module, not a second use of one of these.
disease_term:
  preferred_term: black widow spider envenomation
  term:
    id: MONDO:0800176
    label: black widow spider envenomation
synonyms:
- latrodectism
- widow spider envenomation
- black widow envenomation
parents:
- Envenomation
- Arthropod Envenomation
clinical_burden:
  burden_level: VARIABLE
  rationale: >-
    Most exposures are minor and managed without a healthcare visit at all,
    but a minority produce pain severe enough to require intravenous opioids,
    and a small number produce myocarditis or rhabdomyolysis. VARIABLE rather
    than LOW because the distribution is genuinely wide and symptoms are more
    severe in young children; VARIABLE rather than MODERATE because the modal
    case is minor. Deaths from the envenomation itself are not reported in the
    sources cited here - but the largest series records a death from the
    antivenom, which is a different claim and is curated on that treatment.
  evidence:
  - reference: PMID:39670790
    reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Poison center data indicate that most black widow spider exposures result in minor consequences."
    explanation: The low-burden end of the distribution, across 15,299 reported exposures.
  - reference: PMID:39670790
    reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Hospital admission was required for 10.0% of exposures."
    explanation: >-
      The other end, and the reason the level is not LOW - one in ten reported
      exposures is admitted.
  - reference: PMID:29133072
    reference_title: "Treatment of pediatric black widow spider envenomation: A national poison center's experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Symptoms tend to be more severe in young children and adults."
    explanation: The age dependence this rationale invokes, which would otherwise be uncited.
mechanistic_hypotheses:
- hypothesis_group_id: pore_mediated_calcium_influx
  hypothesis_label: Pore-mediated calcium influx drives the exocytosis
  status: CANONICAL
  description: >-
    The tetrameric toxin inserts into the presynaptic membrane and forms a
    cation-selective channel; calcium entering through that channel triggers
    the massive exocytosis. This is the structurally resolved account and the
    one the cryo-EM work describes in detail.
  evidence:
  - reference: PMID:10865131
    reference_title: Alpha-latrotoxin and its receptors CIRL (latrophilin) and neurexin 1 alpha mediate effects on secretion through multiple mechanisms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "The stimulation of secretion by alpha-latrotoxin in neuroendocrine cells is a consequence of Ca(2+) influx through these alpha-latrotoxin-induced channels."
    explanation: >-
      States the canonical account - the channel is the route, and calcium
      influx through it is the trigger.
- hypothesis_group_id: receptor_mediated_secretion
  hypothesis_label: A receptor-signalling arm acts independently of the pore
  status: ALTERNATIVE
  description: >-
    A second route in which the toxin's receptors do more than tether it:
    engagement of latrophilin/CIRL, a G-protein-coupled receptor, stimulates
    secretion without requiring calcium entry through a pore. It began as an
    inference from a negative observation - exocytosis happens in the complete
    absence of extracellular calcium, which the pore account cannot explain -
    and has since been given a full cascade, demonstrated with a pore-deficient
    toxin mutant so that the pore cannot be doing the work. Recorded as
    ALTERNATIVE rather than CANONICAL because what has been demonstrated is
    spontaneous quantal release at the mouse neuromuscular junction; no work
    apportions the two arms in a human envenomation.
  evidence:
  - reference: PMID:10382267
    reference_title: Mechanisms of alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "However, this mechanism fails to explain exocytosis which occurred in the complete absence of extracellular calcium."
    explanation: >-
      The observation that requires a second arm at all, stated as the failure
      of the first. This is what makes the two accounts rival explanations
      rather than a single chain.
  - reference: PMID:10865131
    reference_title: Alpha-latrotoxin and its receptors CIRL (latrophilin) and neurexin 1 alpha mediate effects on secretion through multiple mechanisms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "In addition to channel formation, alpha-latrotoxin enhances secretion in permeabilized cells through interaction with the plasma membrane receptor CIRL/latrophilin."
    explanation: >-
      Secretion enhanced through the receptor in permeabilized cells, which is
      the pore-independent claim.
  - reference: PMID:9430716
    reference_title: Neurexin I alpha is a major alpha-latrotoxin receptor that cooperates in alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "The action of alpha-latrotoxin may therefore be mediated by independent parallel pathways, of which the CIRL/latrophilin pathway is sufficient for neurotransmitter release, whereas the neurexin I alpha pathway contributes to the Ca(2+)-dependent action of alpha-latrotoxin."
    explanation: >-
      The strongest evidence for this hypothesis, and it is genetic rather than
      pharmacological: in neurexin-1alpha knockout mice the latrophilin pathway
      alone is sufficient for release. Note what this does and does not say -
      "independent parallel pathways" is about the two receptors, not about
      pore versus signalling, so it establishes that the latrophilin arm can
      carry the effect without establishing how.
  - reference: PMID:9430716
    reference_title: Neurexin I alpha is a major alpha-latrotoxin receptor that cooperates in alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "In cultured hippocampal neurons, alpha-latrotoxin was still capable of activating neurotransmission in the absence of neurexin I alpha."
    explanation: >-
      The knockout result itself - losing one receptor family does not abolish
      the toxin's action.
  - reference: PMID:42121922
    reference_title: "Latrophilin-1-Mediated G(αq) Signaling, Store-Operated Ca(2+) Entry, and Ca(V)2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "Here, we dissect the LPHN1 signaling pathway at the vertebrate neuromuscular junction, using the pore-deficient αLTX mutant LTXN4C as a selective agonist."
    explanation: >-
      The design that makes this arm testable rather than merely inferred: a
      toxin mutant that cannot form a pore, used as the agonist, so any
      exocytosis observed cannot be attributed to the pore.
  - reference: PMID:42121922
    reference_title: "Latrophilin-1-Mediated G(αq) Signaling, Store-Operated Ca(2+) Entry, and Ca(V)2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "This store depletion activates store-operated Ca2+ entry (SOCE), providing sustained Ca2+ required for LTXN4C-induced burst-like exocytosis."
    explanation: >-
      Closes the cascade to exocytosis. Read the scope carefully - this is
      spontaneous quantal release at the mouse neuromuscular junction, not the
      massive discharge of an envenomation.
pathophysiology:
- name: Alpha-Latrotoxin Binding to Presynaptic Receptors
  biological_scale: MOLECULAR
  description: >-
    Alpha-latrotoxin binds two structurally unrelated families of presynaptic
    receptor - neurexin-1alpha, which binds calcium-dependently, and
    latrophilin/CIRL, a G-protein-coupled receptor that binds without calcium.
    Their shared and best-evidenced function is tethering: holding the toxin
    at the membrane so that it can insert. The evidence for that is unusually
    clean, because a chimera carrying only the extracellular domain of CIRL-1
    on an unrelated viral transmembrane anchor produced the same channels as
    the wild-type receptor.
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  - preferred_term: autonomic and neurosecretory neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Alpha-Latrotoxin Tetramer Insertion and Pore Formation
    causal_link_type: DIRECT
    hypothesis_groups:
    - pore_mediated_calcium_influx
    description: >-
      Receptor tethering raises the efficiency of membrane insertion by orders
      of magnitude; insertion is inefficient without it.
    evidence:
    - reference: PMID:10692492
      reference_title: "Calcium-independent receptor for alpha-latrotoxin and neurexin 1alpha [corrected] facilitate toxin-induced channel formation: evidence that channel formation results from tethering of toxin to membrane."
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "We propose that alpha-latrotoxin receptors recruit toxin to facilitate its insertion across the membrane and that alpha-latrotoxin itself controls the conductance properties of the channels it produces."
      explanation: >-
        States the causal role this edge asserts - recruitment for insertion -
        and separates it from the conductance, which is the toxin's own.
  - target: Latrophilin Receptor Signalling at the Nerve Terminal
    causal_link_type: DIRECT
    hypothesis_groups:
    - receptor_mediated_secretion
    description: >-
      Under the alternative account the same binding event initiates receptor
      signalling rather than merely positioning the toxin.
  - target: Pain
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pain begins where the venom is deposited, so it is drawn from the first
      node rather than from the systemic ones. Unknown intermediates on
      purpose: the entry models no local sensory-terminal node, and no cited
      source traces the route from toxin binding to nociception.
  evidence:
  - reference: PMID:39362850
    reference_title: Structural basis of α-latrotoxin transition to a cation-selective pore.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: BACKGROUND
    snippet: "This 130 kDa toxin binds to receptors at presynaptic nerve terminals and triggers a massive release of neurotransmitters."
    explanation: >-
      The target and the outcome in one sentence. BACKGROUND because it is the
      structural paper's framing of established biology rather than its own
      cryo-EM result.
  - reference: PMID:9430716
    reference_title: Neurexin I alpha is a major alpha-latrotoxin receptor that cooperates in alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: BACKGROUND
    snippet: "A surprising finding was the biochemical description of two distinct cell surface proteins that bind alpha-latrotoxin with nanomolar affinities; Neurexin I alpha binds alpha-latrotoxin in a Ca(2+)-dependent manner, and CIRL/latrophilin binds in a Ca(2+)-independent manner."
    explanation: >-
      Both receptor families and the binding property that distinguishes them,
      which is the claim this node makes.
  - reference: PMID:10382267
    reference_title: Mechanisms of alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "Neurexins are single transmembrane proteins which bind to alpha-latrotoxin in a calcium-dependent manner and also interact with the synaptic vesicle protein, synaptotagmin. On the other hand, latrophilin is a seven-transmembrane protein and belongs to the family of G-protein-coupled receptors."
    explanation: >-
      The two receptor families and the property that distinguishes them, which
      is why the calcium-free experiments discriminate between the hypotheses.
- name: Alpha-Latrotoxin Tetramer Insertion and Pore Formation
  biological_scale: MOLECULAR
  description: >-
    In the presence of calcium or magnesium the toxin assembles into a
    C4-symmetric tetramer, then undergoes a large conformational change: four
    N-terminal helical bundles refold into a rigid coiled-coil stalk that
    drives a pair of helices into the bilayer, opening a cation-permeable
    channel. The prepore and pore states have both been resolved by cryo-EM,
    so this is a structurally described event rather than an inferred one.
  molecular_functions:
  - preferred_term: cation-selective channel formed by an exogenous toxin
    modifier: GAIN_OF_FUNCTION
    term:
      id: GO:0005261
      label: monoatomic cation channel activity
  - preferred_term: toxin activity of alpha-latrotoxin
    term:
      id: GO:0090729
      label: toxin activity
  downstream:
  - target: Presynaptic Calcium Influx
    causal_link_type: DIRECT
    hypothesis_groups:
    - pore_mediated_calcium_influx
  evidence:
  - reference: PMID:10625427
    reference_title: "Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores."
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "We discovered that alpha-latrotoxin exists in two oligomeric forms: it is dimeric in EDTA but forms tetramers in the presence of Ca2+ or Mg2+."
    explanation: The divalent-cation dependence of tetramerization, which is the first step of this node.
  - reference: PMID:10625427
    reference_title: "Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores."
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "The C4-symmetric tetramers represent the active form of alpha-latrotoxin; they have an axial channel and can insert into lipid bilayers with their hydrophobic base, providing the first model of alpha-latrotoxin pore formation."
    explanation: The tetramer as the active, membrane-inserting form.
  - reference: PMID:39362850
    reference_title: Structural basis of α-latrotoxin transition to a cation-selective pore.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "Four distinct helical bundles rearrange and together form a highly stable, 15 nm long, cation-impermeable coiled-coil stalk. This stalk, in turn, positions an N-terminal pair of helices within the membrane, thereby enabling the assembly of a cation-permeable channel."
    explanation: >-
      The prepore-to-pore transition in structural detail, and the source of
      the two resolutions quoted elsewhere in this entry.
- name: Latrophilin Receptor Signalling at the Nerve Terminal
  biological_scale: MOLECULAR
  description: >-
    The alternative arm, and no longer a black box. Engagement of
    latrophilin-1 couples to Gaq and phospholipase C, generating IP3 that
    releases calcium from intracellular stores through IP3 receptors; the
    resulting store depletion opens store-operated calcium entry, which
    supplies the sustained calcium that exocytosis needs. The cascade was
    delineated at the mouse neuromuscular junction using a pore-deficient
    toxin mutant, so the pore is excluded by construction rather than by
    argument. What this does not establish is how much of a human envenomation
    runs through it.
  biological_processes:
  - preferred_term: G protein-coupled receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007186
      label: G protein-coupled receptor signaling pathway
  downstream:
  - target: Unregulated Neurotransmitter Exocytosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - receptor_mediated_secretion
    description: >-
      The intermediates are named: Gaq, phospholipase C, IP3, IP3-receptor
      store release, then store-operated calcium entry. INDIRECT rather than
      DIRECT because that is five steps, and KNOWN rather than UNKNOWN because
      each was tested rather than assumed.
    evidence:
    - reference: PMID:42121922
      reference_title: "Latrophilin-1-Mediated G(αq) Signaling, Store-Operated Ca(2+) Entry, and Ca(V)2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "Upon activation, LPHN1 engages the Gαq-phospholipase C pathway to generate inositol 1,4,5-trisphosphate (IP3), triggering Ca2+ release from intracellular stores via IP3 receptors."
      explanation: >-
        The intermediates this edge claims, named and ordered, from
        electrophysiology in latrophilin-1 knockout mice with pharmacological
        inhibitors and calcium imaging.
  evidence:
  - reference: PMID:10692492
    reference_title: "Calcium-independent receptor for alpha-latrotoxin and neurexin 1alpha [corrected] facilitate toxin-induced channel formation: evidence that channel formation results from tethering of toxin to membrane."
    supports: REFUTE
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "An analysis of CIRL-1 mutants indicated that channel formation in HEK293 cells is unlikely to be transduced by a G-protein-dependent mechanism."
    explanation: >-
      REFUTE, and narrowly: what it excludes is a G-protein-dependent route to
      *channel formation*, in HEK293 cells overexpressing CIRL-1. This node
      claims a G-protein route to *secretion*, which is a different claim in a
      different system, and PMID:42121922 has since demonstrated exactly that
      route at the neuromuscular junction. Kept because it is a real negative
      result about a neighbouring claim and a reader should see it; it is not
      evidence that this arm does not exist.
- name: Presynaptic Calcium Influx
  biological_scale: CELLULAR
  description: >-
    Calcium enters the terminal through the toxin's own channel, a high
    conductance pore measured at around 400 pS, bypassing the voltage-gated
    calcium channels that normally gate release.
  biological_processes:
  - preferred_term: calcium ion transmembrane transport
    modifier: INCREASED
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  downstream:
  - target: Unregulated Neurotransmitter Exocytosis
    causal_link_type: DIRECT
    hypothesis_groups:
    - pore_mediated_calcium_influx
  evidence:
  - reference: PMID:10692492
    reference_title: "Calcium-independent receptor for alpha-latrotoxin and neurexin 1alpha [corrected] facilitate toxin-induced channel formation: evidence that channel formation results from tethering of toxin to membrane."
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "we demonstrate that the interaction of alpha-latrotoxin with CIRL-1 produces a high conductance channel that permits increases in cytosolic Ca(2+)"
    explanation: >-
      States what this node claims - the channel admits calcium into the
      cytosol - rather than only reporting a conductance.
  - reference: PMID:10692492
    reference_title: "Calcium-independent receptor for alpha-latrotoxin and neurexin 1alpha [corrected] facilitate toxin-induced channel formation: evidence that channel formation results from tethering of toxin to membrane."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "alpha-Latrotoxin interaction with CIRL-1 transiently expressed in bovine chromaffin cells produced a 400-pS channel, which rarely closed under Ca(2+)-free conditions."
    explanation: >-
      The measured conductance. INDIRECT because it was measured in
      CIRL-1-overexpressing bovine chromaffin cells, not at a presynaptic
      terminal, which is what this node is about.
- name: Unregulated Neurotransmitter Exocytosis
  biological_scale: CELLULAR
  description: >-
    The convergence point of both hypothesis arms, and the event that produces
    the whole clinical syndrome. Vesicular acetylcholine and catecholamines are
    discharged continuously rather than in response to action potentials.
  biological_processes:
  - preferred_term: synaptic vesicle exocytosis
    modifier: INCREASED
    term:
      id: GO:0016079
      label: synaptic vesicle exocytosis
  - preferred_term: neurotransmitter secretion
    modifier: INCREASED
    term:
      id: GO:0007269
      label: neurotransmitter secretion
  downstream:
  - target: Synaptic Vesicle Pool Depletion
    causal_link_type: DIRECT
  - target: Sustained Motor End-Plate Activation
    causal_link_type: DIRECT
  - target: Autonomic Neurotransmitter Excess
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:10382267
    reference_title: Mechanisms of alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "The major component of black widow spider venom, alpha-latrotoxin, triggers massive exocytosis in a variety of neurosecretory cells."
    explanation: The node's central claim, and that it is not restricted to one cell type.
- name: Synaptic Vesicle Pool Depletion
  biological_scale: CELLULAR
  description: >-
    Sustained exocytosis outrunning endocytic retrieval empties the terminal of
    both transmitter quanta and the vesicles themselves, with vesicle membrane
    left incorporated into the axolemma. Read the limitation, because it is
    load-bearing: the experiment showing this was run in the *absence* of
    extracellular calcium, and the same paper's calcium-present control found
    active recycling of both quanta and vesicles with no depletion at all.
    Calcium is present in an envenomated patient, so this node describes a
    demonstrated capability of the toxin rather than an established step of the
    human syndrome. No source cited here establishes that vesicle depletion is
    what makes latrodectism self-limited.
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  evidence:
  - reference: PMID:1967610
    reference_title: Redistribution of synaptophysin and synapsin I during alpha-latrotoxin-induced release of neurotransmitter at the neuromuscular junction.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "In nerve-muscle preparations treated for 1 h with a low dose of alpha-latrotoxin in the absence of extracellular Ca2+ (a condition under which nerve terminals are depleted of both quanta of neurotransmitter and synaptic vesicles), the immunolabeling for both proteins was distributed along the axolemma."
    explanation: >-
      Depletion of both quanta and vesicles, with vesicle membrane proteins
      redistributed to the axolemma. INDIRECT because the condition is
      calcium-free and an envenomated patient is not - see the refuting item
      below, which is the same paper's own control.
  - reference: PMID:1967610
    reference_title: Redistribution of synaptophysin and synapsin I during alpha-latrotoxin-induced release of neurotransmitter at the neuromuscular junction.
    supports: REFUTE
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "When the same dose of alpha-latrotoxin was applied in the presence of extracellular Ca2+, the immunoreactivity patterns resembled those obtained in resting preparations"
    explanation: >-
      The same paper's calcium-present control, which is the condition that
      applies in a patient, and in which retrieval kept pace. REFUTE against
      reading this node as an established step of the human syndrome. Recorded
      rather than omitted because the supporting quote alone would misrepresent
      the paper.
- name: Sustained Motor End-Plate Activation
  biological_scale: TISSUE
  description: >-
    Continuous acetylcholine release at the neuromuscular junction holds
    skeletal muscle in involuntary contraction. The cramping spreads
    contiguously from the bitten limb to the trunk, which is the feature that
    most often distinguishes latrodectism from an acute abdomen at the bedside.
  downstream:
  - target: Muscle spasm
    causal_link_type: DIRECT
  - target: Rigidity
    causal_link_type: DIRECT
  - target: Abdominal pain
    causal_link_type: DIRECT
  - target: Rhabdomyolysis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Blepharospasm
    causal_link_type: DIRECT
    description: >-
      The muscular component of facies latrodectismica - sustained orbicularis
      oculi contraction, the same end-plate mechanism as the cramping
      elsewhere.
  evidence:
  - reference: PMID:29133072
    reference_title: "Treatment of pediatric black widow spider envenomation: A national poison center's experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Black widow species (Latrodectus species) envenomation can produce a syndrome characterized by painful muscle rigidity and autonomic disturbances."
    explanation: >-
      The two clinical arms this node and the next one split into. BACKGROUND
      because it is the study's framing rather than its own result.
- name: Autonomic Neurotransmitter Excess
  biological_scale: ORGANISM
  description: >-
    The same unregulated release at autonomic terminals - acetylcholine at
    ganglia and exocrine glands, catecholamines at postganglionic sympathetic
    terminals - produces a mixed autonomic picture rather than a purely
    sympathetic one. Hypertension, tachycardia and diaphoresis sit alongside
    nausea, vomiting and lacrimation.
  downstream:
  - target: Hypertension
    causal_link_type: DIRECT
  - target: Tachycardia
    causal_link_type: DIRECT
  - target: Hyperhidrosis
    causal_link_type: DIRECT
  - target: Nausea
    causal_link_type: DIRECT
  - target: Vomiting
    causal_link_type: DIRECT
  - target: Epiphora
    causal_link_type: DIRECT
    description: >-
      Cholinergic drive at the lacrimal gland, the same exocrine mechanism as
      the salivation and bronchial secretion described for autonomic excess.
  - target: Periorbital edema
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Part of facies latrodectismica. Drawn with unknown intermediates because
      the source describes the sign without establishing what produces the
      oedema; a local autonomic vasomotor effect is the usual explanation and
      is not demonstrated.
  - target: Envenomation-Associated Myocardial Injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:25978056
    reference_title: "The black widow spider bite: differential diagnosis, clinical manifestations, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The widow venom, a powerful neurotoxin known as a-latrotoxin, causes muscle pain, diaphoresis, tachycardia, flushing, and hypertension."
    explanation: >-
      Names four of the autonomic features wired downstream of this node, and
      attributes them to the toxin rather than to pain alone.
  - reference: PMID:21762981
    reference_title: Spider bite.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Latrodectism results from bites by widow spiders (Latrodectus spp) and causes local, regional, or generalised pain associated with non-specific symptoms and autonomic effects."
    explanation: The authoritative review's statement of the syndrome, including its autonomic component.
- name: Envenomation-Associated Myocardial Injury
  biological_scale: TISSUE
  description: >-
    A rare complication: myocarditis with raised troponin and, in reported
    cases, echocardiographic abnormality. Deliberately named for the
    association rather than for a mechanism - a catecholamine-mediated route is
    the usual explanation and is plausible given the adrenergic excess
    upstream, but no source cited here demonstrates it, so the node does not
    assert it. Curated because it is the one route by which a self-limited
    envenomation becomes an intensive care problem.
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Myocarditis
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34027976
    reference_title: "Case Report: Soldier With Latrodectism After Black Widow Spider Bite During a Field Training Exercise."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Latrodectism is a severe systemic manifestation of the envenomation that includes severe abdominal pain mimicking acute surgical abdomen and, in rare cases, could lead to acute myocarditis and rhabdomyolysis."
    explanation: >-
      Places myocarditis and rhabdomyolysis as rare complications of the
      systemic syndrome, which is what this node and the rhabdomyolysis edge
      above assert.
phenotypes:
- category: Musculoskeletal
  name: Muscle spasm
  phenotype_term:
    preferred_term: Muscle cramping
    term:
      id: HP:0003394
      label: Muscle spasm
  description: >-
    The defining feature. Severe involuntary cramping that begins near the bite
    and spreads to the abdomen, back and thighs.
  evidence:
  - reference: PMID:22058673
    reference_title: "The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Black widow spider bites cause a characteristic envenomation syndrome consisting of severe pain, muscle cramping, abdominal pain, and back pain."
    explanation: Names cramping as a defining component of the syndrome.
- category: Musculoskeletal
  name: Rigidity
  phenotype_term:
    preferred_term: Muscle rigidity
    term:
      id: HP:0002063
      label: Rigidity
  description: Painful rigidity, classically of the abdominal wall, mimicking peritonitis.
  evidence:
  - reference: PMID:29133072
    reference_title: "Treatment of pediatric black widow spider envenomation: A national poison center's experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "envenomation can produce a syndrome characterized by painful muscle rigidity and autonomic disturbances"
    explanation: Rigidity named as a defining feature of the syndrome.
- category: Gastrointestinal
  name: Abdominal pain
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  description: >-
    Severe enough to be mistaken for a surgical abdomen, and the reason
    latrodectism appears in differential diagnoses of acute abdomen.
  evidence:
  - reference: PMID:34027976
    reference_title: "Case Report: Soldier With Latrodectism After Black Widow Spider Bite During a Field Training Exercise."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "severe abdominal pain mimicking acute surgical abdomen"
    explanation: The clinical mimicry that makes this phenotype diagnostically important.
- category: Cardiovascular
  name: Hypertension
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:25978056
    reference_title: "The black widow spider bite: differential diagnosis, clinical manifestations, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "causes muscle pain, diaphoresis, tachycardia, flushing, and hypertension"
    explanation: Hypertension named among the toxin's autonomic effects.
- category: Cardiovascular
  name: Tachycardia
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: PMID:31492593
    reference_title: Latrodectus Facies After Latrodectus Hesperus Envenomation in a Pediatric Patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "autonomic disturbances, such as tachycardia, hypertension, and diaphoresis"
    explanation: Tachycardia named among the characteristic autonomic disturbances.
- category: Autonomic
  name: Hyperhidrosis
  phenotype_term:
    preferred_term: Diaphoresis
    term:
      id: HP:0000975
      label: Hyperhidrosis
  description: >-
    Sweating, sometimes in a localized or asymmetric distribution near the
    bite, which is a recognised diagnostic clue.
  evidence:
  - reference: PMID:31492593
    reference_title: Latrodectus Facies After Latrodectus Hesperus Envenomation in a Pediatric Patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "autonomic disturbances, such as tachycardia, hypertension, and diaphoresis"
    explanation: Diaphoresis named among the characteristic autonomic disturbances.
- category: Gastrointestinal
  name: Nausea
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:37377825
    reference_title: "Reversible Myocarditis Following Black Widow Spider (Latrodectus spp.) Bite in Egypt: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "The effects of BWS bites ranges from local damage to systemic manifestations including paresthesia, stiffness, abdominal cramps, nausea, vomiting, headache, anxiety, hypertension and tachycardia."
    explanation: >-
      Names nausea among the systemic manifestations. BACKGROUND because it is
      the case report's framing of the syndrome rather than its own finding.
- category: Gastrointestinal
  name: Vomiting
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:37377825
    reference_title: "Reversible Myocarditis Following Black Widow Spider (Latrodectus spp.) Bite in Egypt: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "The effects of BWS bites ranges from local damage to systemic manifestations including paresthesia, stiffness, abdominal cramps, nausea, vomiting, headache, anxiety, hypertension and tachycardia."
    explanation: Names vomiting among the systemic manifestations.
- category: Musculoskeletal
  name: Rhabdomyolysis
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  description: Rare, and reported together with myocarditis and arrhythmia in severe cases.
  evidence:
  - reference: PMID:35435990
    reference_title: "Coexistence of Rhabdomyolysis, Myocarditis and Arrhythmia after Spider Bite: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Rhabdomyolysis after spider bite has been reported in a small number of patients, and myocarditis in even fewer."
    explanation: >-
      Establishes both the occurrence and the rarity, which is what this
      phenotype's description claims.
- category: Cardiovascular
  name: Myocarditis
  phenotype_term:
    preferred_term: Myocarditis
    term:
      id: HP:0012819
      label: Myocarditis
  description: >-
    Reversible in the reported cases cited here, with recovery of ventricular
    function - but not uniformly so, and the literature describes fatal cases.
  evidence:
  - reference: PMID:34027976
    reference_title: "Case Report: Soldier With Latrodectism After Black Widow Spider Bite During a Field Training Exercise."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We report the case of a 26-year-old active duty male soldier evacuated from field training with latrodectism and possible envenomation-induced myocarditis after a suspected BWS bite."
    explanation: The reported case of envenomation-associated myocarditis this phenotype records.
  - reference: PMID:32462634
    reference_title: "Acute Myocarditis After Black Widow Spider Bite: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Cases of myocarditis following a BWS bite are rare but they can be fatal on occasion."
    explanation: >-
      The correction to any impression that this complication is uniformly
      reversible. Cited specifically so the description cannot be read as
      reassurance.
- category: Ophthalmologic
  name: Periorbital edema
  phenotype_term:
    preferred_term: Periorbital edema
    term:
      id: HP:0100539
      label: Periorbital edema
  description: >-
    Part of "facies latrodectismica", a distinctive but rarely described facial
    appearance combining periorbital oedema, lacrimation and blepharospasm.
  evidence:
  - reference: PMID:31492593
    reference_title: Latrodectus Facies After Latrodectus Hesperus Envenomation in a Pediatric Patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "\"Latrodectus facies\" or \"facies latrodectismica\" is an additional distinctive but rarely described clinical finding characterized by periorbital edema, lacrimation, and blepharospasm."
    explanation: Defines the sign and names periorbital oedema as one of its three components.
- category: Dermatologic
  name: Erythema
  phenotype_term:
    preferred_term: Erythema at the bite site
    term:
      id: HP:0010783
      label: Erythema
  description: >-
    A small area of redness at the bite. Deliberately not wired to a mechanism
    node: the entry models nerve-terminal effects, and nothing cited here
    explains the local vascular change, so an edge would be invented rather
    than curated.
  evidence:
  - reference: PMID:37377825
    reference_title: "Reversible Myocarditis Following Black Widow Spider (Latrodectus spp.) Bite in Egypt: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Physical examination revealed a 3 × 2 mm area of erythema at the bite site, board-like abdominal rigidity and hyperactive stretch reflexes."
    explanation: >-
      A measured bite-site finding in a confirmed widow envenomation, and the
      scale is the point - three millimetres by two. No frequency is recorded
      because this is one case.
- category: Dermatologic
  name: Local edema
  phenotype_term:
    preferred_term: Edema at the bite site
    term:
      id: HP:0000969
      label: Edema
  description: >-
    Swelling at the inoculum site, alongside the erythema. Left unwired for the
    same reason as the erythema - the entry models nerve-terminal effects and
    nothing cited traces a route to a local vascular change.
  evidence:
  - reference: PMID:32462634
    reference_title: "Acute Myocarditis After Black Widow Spider Bite: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Patients may experience edema, necrosis, and bacterial superinfection at the inoculum site."
    explanation: >-
      A widow case report's own framing of the local findings. Quoted whole
      rather than trimmed to the edema: the same sentence also claims necrosis
      at the bite, which no other source cited here reports and which is the
      classic loxoscelism finding, so the clause is left visible rather than
      cropped away. Only the edema is curated as a phenotype.
- category: Neurologic
  name: Pain
  phenotype_term:
    preferred_term: Pain at and spreading from the bite site
    term:
      id: HP:0012531
      label: Pain
  description: >-
    The presenting complaint, and the feature that makes latrodectism
    recognisable: pain begins locally and spreads regionally rather than
    staying at a bite that looks like almost nothing.
  evidence:
  - reference: PMID:21762981
    reference_title: Spider bite.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Latrodectism results from bites by widow spiders (Latrodectus spp) and causes local, regional, or generalised pain associated with non-specific symptoms and autonomic effects."
    explanation: >-
      Names the local-to-regional-to-generalised progression, attributed to
      Latrodectus specifically rather than to spider bite in general.
- category: Ophthalmologic
  name: Epiphora
  phenotype_term:
    preferred_term: Lacrimation
    term:
      id: HP:0009926
      label: Epiphora
  description: >-
    The third component of facies latrodectismica, and the one attributable to
    cholinergic drive at the lacrimal gland rather than to muscle.
  evidence:
  - reference: PMID:31492593
    reference_title: Latrodectus Facies After Latrodectus Hesperus Envenomation in a Pediatric Patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "characterized by periorbital edema, lacrimation, and blepharospasm"
    explanation: Names lacrimation as the third component of the sign.
- category: Ophthalmologic
  name: Blepharospasm
  phenotype_term:
    preferred_term: Blepharospasm
    term:
      id: HP:0000643
      label: Blepharospasm
  description: The second component of facies latrodectismica.
  evidence:
  - reference: PMID:31492593
    reference_title: Latrodectus Facies After Latrodectus Hesperus Envenomation in a Pediatric Patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "characterized by periorbital edema, lacrimation, and blepharospasm"
    explanation: Names blepharospasm as a component of the sign.
environmental:
- name: Bite by a female widow spider
  description: >-
    The exposure is an injection through the chelicerae into subcutaneous
    tissue. Only the mature female is capable of clinically significant
    envenomation. Bites are domestic and occupational rather than exotic -
    woodpiles, outbuildings, stored furniture - and cluster in warm months and
    warm states.
  exposure_term:
    preferred_term: exposure to alpha-latrotoxin by spider bite
    term:
      id: ECTO:0000730
      label: exposure to neurotoxin
  notes: >-
    Bound to the generic `ECTO:0000730` because ECTO has no spider, venom, bite
    or arthropod exposure class. OLS `q=venom, ontology=ecto` returns only
    CHEBI and FOODON hits (`CHEBI:78505` venom, `CHEBI:30751` formic acid,
    `CHEBI:6736` melittin); `q=spider, ontology=ecto` returns `CHEBI:6651`
    malathion and `FOODON:03414899` terrestrial invertebrate; `q=bite,
    ontology=ecto` returns `CHEBI:78505` venom, `ExO:0000060` injection route
    and `GO:0071626` mastication; `q=arthropod, ontology=ecto` returns UBERON,
    NCBITaxon and CHEBI terms only. None is an exposure class.
  influences_mechanisms:
  - target: Alpha-Latrotoxin Binding to Presynaptic Receptors
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      The bite is the route by which the toxin reaches presynaptic terminals;
      nothing in the chain happens without it.
    evidence:
    - reference: PMID:39670790
      reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "The black widow spider, Latrodectus mactans, stands out as one of the most medically significant arachnids due to its extensive geographic distribution in the United States and its ability to produce a potent neurotoxin, α-latrotoxin."
      explanation: Names the exposure and the toxin it delivers, which is what this link asserts.
  evidence:
  - reference: PMID:39670790
    reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Exposures occurred with higher frequency in warm-weather states and during summer months."
    explanation: The geographic and seasonal distribution of the exposure, across 15,299 reported cases.
treatments:
- name: Opioid analgesia
  description: >-
    The mainstay, and the comparator RAVE-II measured antivenom against.
    Pain in latrodectism is characteristically refractory to simple analgesics,
    so intravenous opioids are the practical first line.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: morphine
      term:
        id: CHEBI:17303
        label: morphine
  target_mechanisms:
  - target: Sustained Motor End-Plate Activation
    treatment_effect: MODULATES
    description: >-
      Drawn at the node that generates the pain rather than upstream, and
      MODULATES rather than INHIBITS on purpose - opioids do nothing to the
      toxin or to transmitter release, they raise the threshold at which the
      resulting nociception is felt.
    evidence:
    - reference: PMID:1351707
      reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "Fifty-five percent of patients initially receiving IV morphine and 70% of those initially receiving both IV morphine and benzodiazepines obtained symptomatic relief without additional medication."
      explanation: >-
        INDIRECT: a therapeutic response cited in support of the node it acts
        on. The series is retrospective and uncontrolled, so the numbers
        describe practice rather than isolating the drug's effect.
  evidence:
  - reference: PMID:22058673
    reference_title: "The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "The significant pain associated with envenomation is often refractory to traditional analgesics."
    explanation: Why opioids rather than simple analgesia, stated as the clinical problem.
- name: Benzodiazepine muscle relaxation
  description: >-
    Given with opioids rather than instead of them. In the largest published
    series the combination outperformed opioid alone, and benzodiazepines are
    the second most frequently recorded therapy in US poison centre data.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: diazepam
      term:
        id: CHEBI:49575
        label: diazepam
    - preferred_term: benzodiazepine
      term:
        id: NCIT:C1012
        label: Benzodiazepine
  target_mechanisms:
  - target: Sustained Motor End-Plate Activation
    treatment_effect: MODULATES
    description: >-
      Central muscle relaxation against the sustained contraction this node
      produces.
    evidence:
    - reference: PMID:1351707
      reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "Fifty-five percent of patients initially receiving IV morphine and 70% of those initially receiving both IV morphine and benzodiazepines obtained symptomatic relief without additional medication."
      explanation: >-
        The same sentence supports both drugs, and the comparison within it -
        70% versus 55% - is what justifies adding the benzodiazepine.
        INDIRECT, and uncontrolled.
  evidence:
  - reference: PMID:39670790
    reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The most common therapies received were wound care (43.7%) and benzodiazepines (18.6%)."
    explanation: >-
      Benzodiazepines at 18.6%, second only to wound care. The abstract does
      not report opioid use, so this establishes frequency in practice rather
      than that benzodiazepines are the commonest drug given.
- name: Equine antivenom
  description: >-
    The contested treatment. Four studies bear on it and they do not
    agree, which is curated here rather than resolved: a large retrospective series reporting
    resolution in about half an hour, a route-comparison trial whose authors
    concluded antivenom may add nothing over placebo, a placebo-controlled
    trial in 224 patients finding no benefit over standardised analgesia, and a
    second placebo-controlled trial in 60 patients meeting its primary
    endpoint. The entry records all four and the reasons they may differ.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: antivenom administration
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  notes: >-
    Bound to the generic `NCIT:C15986` because NCIT has no antivenom class
    other than a product-specific one: OLS `q=Antivenin, ontology=ncit`
    returns only `NCIT:C87794` Coral Snake (Micrurus fulvius) Immune Globulin
    Antivenin (Equine), which names a different product. The existing
    `Snakebite_Envenoming` entry binds the same generic term for antivenom
    administration.
  target_mechanisms:
  - target: Alpha-Latrotoxin Binding to Presynaptic Receptors
    treatment_effect: INHIBITS
    description: >-
      Antivenom neutralises circulating toxin, so it acts upstream of the
      receptor - which is also the likeliest reason the trials disagree. By the
      time a patient presents in severe pain the binding and insertion steps
      have already happened, and neutralising toxin that has not yet bound
      cannot undo them.
    evidence:
    - reference: PMID:11407496
      reference_title: "Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "Redback spider antivenom is effective in neutralizing the lethal effects of L. hesperus and L. mactans venoms in a mouse envenomation model."
      explanation: >-
        Neutralisation is the mechanism this edge asserts. INDIRECT because it
        is a mouse lethality assay rather than a measurement at the receptor
        and the antigen was premixed with antibody, which is the condition the
        companion item below records.
    - reference: PMID:11407496
      reference_title: "Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "While this study is limited by the optimized premixing of antigen with antibody"
      explanation: >-
        The authors' own caveat, and it is the same point this edge makes:
        premixing guarantees the antivenom meets the toxin before the toxin
        meets a receptor, which is exactly the condition a patient presenting
        hours after a bite does not satisfy. Quoted because it strengthens the
        edge's stated limitation rather than the treatment's case.
  evidence:
  - reference: PMID:1351707
    reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Fifty-eight patients received antivenin with complete resolution of symptoms in a mean time of 31 +/- 26.7 minutes."
    explanation: >-
      The positive retrospective signal, and the one clinicians most often
      cite. INDIRECT and uncontrolled - there is no comparator arm inside this
      number, and a self-limited syndrome will resolve on its own.
  - reference: PMID:24999282
    reference_title: "Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The addition of antivenom to standardized analgesia in patients with latrodectism did not significantly improve pain or systemic effects."
    explanation: >-
      The largest placebo-controlled trial, and it is negative. REFUTE against
      the claim that antivenom adds benefit on top of adequate analgesia -
      which is the claim that matters clinically, since analgesia is given
      either way.
  - reference: PMID:24999282
    reference_title: "Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Two hours after treatment, 26 of 112 patients (23%) from the placebo arm had a clinically significant improvement in pain versus 38 of 112 (34%) from the antivenom arm (difference in favor of antivenom 10.7%; 95% confidence interval -1.1% to 22.6%; P=.10)."
    explanation: >-
      The numbers behind that conclusion. Worth reading rather than
      summarising: the point estimate favours antivenom by 10.7 points and the
      interval only just crosses zero, so this is an underpowered null as much
      as a demonstration of no effect.
  - reference: PMID:30926190
    reference_title: "The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')(2) Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "There were 15 treatment failures in the antivenom group and 24 in the placebo group (P=.019)."
    explanation: >-
      The second placebo-controlled trial, and it is positive on its primary
      endpoint. Note the endpoint differs from RAVE-II's: sustained pain
      reduction over 48 hours rather than improvement at 2 hours.
  - reference: PMID:30926190
    reference_title: "The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')(2) Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The rate of symptom improvement in the placebo group was higher than expected, which may be related to enrollment criteria or placebo effect."
    explanation: >-
      The authors' own caveat on their positive result, quoted so the entry
      does not present it as cleaner than its investigators did.
  - reference: PMID:24999282
    reference_title: "Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Acute systemic hypersensitivity reactions occurred in 4 of 112 patients (3.6%) receiving antivenom."
    explanation: >-
      The cost side of the decision. Cited as SUPPORT for the harm claim, not
      for efficacy.
  - reference: PMID:1351707
    reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "One patient died of severe bronchospasm after receiving antivenin."
    explanation: >-
      A death caused by the treatment, in the same series that supplies this
      entry's strongest positive signal for it. REFUTE against a favourable
      risk-benefit reading. Recorded here rather than left out because a
      treatment framed as a risk-benefit judgement cannot omit the fatal
      outcome in its own best source.
  - reference: PMID:18400776
    reference_title: "A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Furthermore, antivenom may provide no benefit over placebo."
    explanation: >-
      A third randomised trial, and note where this sentence comes from - RAVE-I
      compared intravenous with intramuscular administration, not antivenom
      with placebo, so this is the trialists' inference from their own null
      route comparison rather than a placebo-controlled result. It is the
      observation that motivated RAVE-II.
  - reference: PMID:21762981
    reference_title: Spider bite.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Antivenoms are an important treatment for spider envenomation but have been less successful than have those for snake envenomation, with concerns about their effectiveness for both latrodectism and loxoscelism."
    explanation: >-
      The field's own summary of where this stands. `quote_role:
      REVIEW_SYNTHESIS` already records that the sentence is a review's
      assessment rather than a study this paper ran, so `evidence_source`
      grades the human clinical evidence the assessment is about.
- name: Calcium gluconate
  description: >-
    Historical, and recorded because it was standard practice rather than
    despite it. Intravenous calcium was for years the recommended first-line
    treatment for severe envenomation; the largest series tested it against
    opioids and found it did not work.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: calcium gluconate
      term:
        id: CHEBI:3309
        label: calcium gluconate
  evidence:
  - reference: PMID:1351707
    reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Calcium gluconate was not effective in providing symptomatic relief in this series, with 96% of the grade 2 and 3 envenomations treated initially with calcium gluconate requiring the addition of IV opioids or other analgesics for symptomatic relief."
    explanation: >-
      REFUTE, and quantified: 96% of patients given calcium first needed
      something else anyway. No target_mechanisms edge is drawn, because on
      this evidence it does not act on the pathograph at all.
  - reference: PMID:1351707
    reference_title: "Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Although calcium gluconate usually has been considered the first-line treatment of severe envenomations by black widow spiders, we found it ineffective for pain relief compared with a combination of IV opioids and benzodiazepines."
    explanation: >-
      States both the former standard and the finding against it, which is why
      this treatment is curated rather than omitted.
biochemical:
- name: Creatine kinase
  presence: INCREASED
  biomarker_term:
    preferred_term: creatine kinase
    term:
      id: NCIT:C113245
      label: Creatine Kinase
  notes: >-
    The only laboratory marker this entry curates, and deliberately so. CK is
    measured when rhabdomyolysis is suspected rather than to diagnose
    latrodectism, which is a clinical diagnosis; the entry has no diagnostic
    biomarker to offer because none exists.
  evidence:
  - reference: PMID:35435990
    reference_title: "Coexistence of Rhabdomyolysis, Myocarditis and Arrhythmia after Spider Bite: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "In laboratory tests, creatine kinase was elevated."
    explanation: The measurement itself, in the reported case of envenomation with rhabdomyolysis.
  readouts:
  - target: Rhabdomyolysis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      CK release reports the muscle injury, and is the reason the complication
      is looked for rather than waited for.
    evidence:
    - reference: PMID:35435990
      reference_title: "Coexistence of Rhabdomyolysis, Myocarditis and Arrhythmia after Spider Bite: A Case Report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "These patients should be evaluated for arrhythmia, rhabdomyolysis and myocarditis."
      explanation: >-
        The authors' recommendation that this is monitored for, which is the
        use context this readout records.
prevalence:
- population: United States
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: NOT_YET_DOCUMENTED
  rate_denominator: POPULATION_PER_YEAR
  notes: >-
    Recorded as a reported-exposure count rather than a rate. 15,299 exposures
    reported to US poison centres over 11 years is roughly 1,400 a year, but
    poison-centre reports are voluntary and capture only the fraction that
    prompts a call, so no per-100,000 figure can be derived from it honestly.
  evidence:
  - reference: PMID:39670790
    reference_title: "Black Widow Spider Exposures: A Retrospective Review of the National Poison Data System 2012-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "During the studied period, a total of 15,299 cases of Latrodectus spp exposures were reported to US poison centers."
    explanation: The exposure count and its source, over a defined 11-year window.
discussions:
- kind: KNOWLEDGE_GAP
  discussion_id: which_receptor_arm_carries_the_effect
  prompt: >-
    Does alpha-latrotoxin drive exocytosis through the pore it forms, through
    receptor signalling, or through both - and in what proportion in a human
    envenomation?
  rationale: >-
    Both arms are supported, and the evidence for each is of a different kind.
    Both arms are now mechanistically described, which is a change from how
    this was framed until recently. The pore's prepore and pore states are
    resolved by cryo-EM to 3.1 and 3.7 Angstrom respectively, and the
    channel's conductance is measured. The receptor arm has its own delineated
    cascade - latrophilin-1 to Gaq-phospholipase C to IP3 to store release to
    store-operated calcium entry - established with a pore-deficient toxin
    mutant in latrophilin-1 knockout mice, which is the cleanest available way
    to isolate it from the pore. What remains open is not whether either arm
    exists but what each contributes in a human envenomation. The receptor
    cascade was characterised for spontaneous quantal release at the mouse
    neuromuscular junction, not for the massive discharge of latrodectism; all
    of the discriminating work is in cultured cells, synaptosomes and mice;
    and nothing in the clinical picture distinguishes the two.
  attaches_to:
  - pathophysiology#Latrophilin Receptor Signalling at the Nerve Terminal
  - mechanistic_hypotheses#receptor_mediated_secretion
  evidence:
  - reference: PMID:10382267
    reference_title: Mechanisms of alpha-latrotoxin action.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: "The molecular details of how alpha-latrotoxin binding is transduced eventually to exocytosis remain to be elucidated."
    explanation: The gap, stated by the review that lays out both receptor families.
- kind: KNOWLEDGE_GAP
  discussion_id: antivenom_efficacy_is_unsettled
  prompt: >-
    Does equine antivenom add anything to adequate analgesia in latrodectism,
    and if the two placebo-controlled trials really disagree, why?
  rationale: >-
    RAVE-II randomised 224 patients against placebo on top of standardised
    analgesia and found no significant benefit. Dart and colleagues randomised
    60 patients against placebo and met their primary endpoint. Four
    candidate explanations remain, and the entry cannot choose between them: a
    different spider and a different antivenom product (Latrodectus hasselti in
    Australia versus L. mactans in the United States - the products' antibody
    formats are not described in either trial abstract, so no comparison of
    them is asserted here); a different primary endpoint (pain improvement at 2
    hours versus sustained reduction over 48 hours); a fourfold difference in
    size, with RAVE-II's confidence interval only just crossing zero; and the
    fact that RAVE-II gave both arms standardised analgesia first, which is a
    harder comparator to beat. The species explanation is the weakest of the
    four: redback antivenom neutralises L. mactans venom in a mouse model, so
    the two products are not obviously aimed at incomparable targets. The
    practical question - whether to give a product that causes systemic
    hypersensitivity in about 1 in 28 recipients, and that killed a patient in
    the largest published series - turns on the answer.
  attaches_to:
  - treatments#Equine antivenom
  evidence:
  - reference: PMID:24999282
    reference_title: "Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "There remains considerable controversy over antivenom treatment."
    explanation: >-
      The trialists' own framing of the question, written before they added
      the largest negative result to it.
  - reference: PMID:11407496
    reference_title: "Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "Redback spider antivenom is effective in neutralizing the lethal effects of L. hesperus and L. mactans venoms in a mouse envenomation model."
    explanation: >-
      Bears directly on the species explanation, and against it: the Australian
      antivenom neutralises both American species' venom in a mouse model, so
      species difference alone is a weak account of why the two trials
      disagree. The species names are the point of the quote, which is why the
      whole sentence is given.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (4)

Record notes

No GeneReviews chapter exists and none is expected: this is an acquired envenomation with no Mendelian basis, so `just check-genereviews` returns NO_CHAPTER for both Bookshelf collections. There is likewise no `genetic:` section. The host proteins that matter here - neurexin-1alpha and latrophilin-1/ADGRL1 - are the toxin's receptors, not disease genes, and no human susceptibility locus has been established; they are curated as mechanism rather than as genetics. Two scope exclusions, recorded as decisions. **The insect- and crustacean-specific latrotoxins are not modelled.** Widow venom contains five latroinsectotoxins and one latrocrustatoxin alongside alpha-latrotoxin; they are irrelevant to human envenomation and appear here only in the sentence establishing that alpha-latrotoxin is the vertebrate-active one. **The local bite lesion is modelled only as far as the sources support.** No tissue-destruction branch is curated: the necrotic-arachnidism picture belongs to Loxosceles, and nothing cited here describes tissue destruction in a widow bite in enough detail to model one. The single source that mentions necrosis at all, `PMID:32462634`, does so in one framing sentence, which is quoted whole under the local oedema phenotype rather than cropped to the convenient half - so the claim is visible rather than hidden, and only the oedema is curated from it. Three local bite-site phenotypes are curated: erythema, local pain and local oedema. The target-pattern localized sweating is not, because no source cited here describes it in a quotable sentence about a widow bite. The frequencies circulating for the local findings are not curated either - they come from an uncited table in the deep-research report rather than from a paper, so each phenotype is cited to a source that states the finding instead. Note also that the obvious erythema sentence in `PMID:21762981` is about *loxoscelism* - Loxosceles, not Latrodectus - so it cannot be cited here, which is the ordinary wrong-disease trap in a review that covers several spiders at once. **No module conformance is declared, and that is a decision rather than an omission.** The two candidate modules both model the wrong direction. `neuromuscular_transmission_failure` is organised around loss of the safety factor of neuromuscular transmission - reduced quantal release - which is what botulinum toxin does and is the precise inverse of what alpha-latrotoxin does. `synaptic_vesicle_cycle` names every one of its nodes for an impairment or deficiency of the release machinery. Latrodectism is pathological *excess* of release by an intact machine driven by an exogenous toxin, so conforming to either would assert the opposite of the mechanism this entry curates. A module for toxin-driven unregulated exocytosis would be a new module, not a second use of one of these.

Review round 2 on PR #12170: scope notes rewritten to match the entry · 2026-09-19T00:58:15Z · View source

Answers review 5253855067, whose only blocking finding is mine and is the same defect class as the one the previous round fixed. Round 1 added a third local bite-site phenotype (Local edema, HP:0000969) without updating the scope paragraph in notes:, which still said two local phenotypes were curated and that local oedema had been left out for want of a quotable source - contradicted by a phenotype 790 lines below citing PMID:32462634. A false justification tells the next reviewer the check was already done, which is exactly why the previous round removed one. The paragraph now says what is true: erythema, local pain and local oedema curated; only the target-pattern localized sweating left out, for want of a quotable sentence about a widow bite; the deep-research report's frequency table not used because the row carries no citation. Also removed the absolute claim that widow bites are characteristically non-necrotic. That is the other half of the unsourced no-ulceration claim deleted from the erythema description in round 1 - PMID:32462634, cited by this entry and quoted under the local oedema phenotype, says patients may experience necrosis at the inoculum site. What survives is the defensible part, that the necrotic-arachnidism picture belongs to Loxosceles, which PMID:21762981 supports, plus an explicit note that the one source mentioning necrosis is quoted whole rather than cropped and that only the oedema is curated from it. No evidence items, snippets, terms or causal edges changed in this round; the diff is notes: prose only. Validation: just validate-disorders passes with 70/70 snippets verified; duplicate-key, entity-ref, causal-target, enum-value, qualifier-term, folded-hyphen and case-collision gates all clean.

Review round 1 on PR #12170: evidence grading, full-sentence snippets, local bite-site phenotypes · 2026-09-19T00:39:22Z · View source

Answers review 5253739817 in one push. Finding 1: the equine-antivenom evidence item carried explanation prose claiming it was graded OTHER while the value said HUMAN_CLINICAL; both items on PMID:11407496 are mouse lethality assays and are now MODEL_ORGANISM, with the explanations rewritten to match. Finding 2: two PMID:11407496 snippets had been trimmed with a justification that the cache disproves - the cached sentence is one continuous line and nothing wraps. The trimmed clause names L. hesperus and L. mactans, which is the claim the antivenom_efficacy_is_unsettled discussion rests on, so both now quote the whole sentence and the invented cache-formatting rationale is gone. That justification was fabricated; recording it here rather than only fixing it. Finding 3: added three local bite-site phenotypes - Erythema (HP:0010783, PMID:37377825, a measured 3x2mm finding in a confirmed widow envenomation), Pain (HP:0012531, PMID:21762981, wired from the binding node as INDIRECT_UNKNOWN_INTERMEDIATES because the entry models no local sensory-terminal node) and Local edema (HP:0000969, PMID:32462634). The frequencies the review quoted (28.6 / 17.9 / 13.6 percent) are not curated: they sit in an uncited table row of the deep-research report, so each phenotype is cited to a source that states the finding rather than to the frequency. The PMID:32462634 sentence also asserts necrosis at the inoculum site, which is the classic loxoscelism finding and which nothing else here reports; it is quoted whole rather than cropped, and the explanation says so. Removed an unsourced negative claim from the erythema description - widow bites do not ulcerate - which no cited source supports and which that same sentence contradicts. Erythema and local edema are deliberately left unwired: nothing cited traces a route from toxin binding to a local vascular change. Validation: just validate passes with 70/70 snippets verified, duplicate-key, entity-ref, causal-target, qualifier-term, enum-value and case-collision gates all clean; 14 of 15 phenotypes causally connected.

Create: Black Widow Spider Envenomation (MONDO:0800176) · 2026-09-18T17:53:50Z · View source

New entry for latrodectism, curated from a claude_code deep-research run committed alongside (47 citations, 20 web searches, 293 s). Mechanism. Alpha-latrotoxin is curated as two competing arms rather than one chain, because the literature genuinely supports two. CANONICAL pore_mediated_calcium_influx: receptor tethering, divalent-cation-dependent tetramerisation, a prepore-to-pore transition resolved by cryo-EM (3.1 and 3.7 Angstrom), calcium influx through the resulting channel, then unregulated exocytosis. ALTERNATIVE receptor_mediated_secretion: latrophilin-1 couples to Gaq-phospholipase C, IP3 releases store calcium, store depletion opens store-operated calcium entry. Causal edges opt in via hypothesis_groups. The alternative is not speculative - it was demonstrated with the pore-deficient toxin mutant LTXN4C in latrophilin-1 knockout mice - but it was characterised for spontaneous quantal release at the mouse neuromuscular junction, not for the massive discharge of an envenomation, and the entry says so in every place it matters. Antivenom is the contested treatment and is curated as a disagreement, not a verdict. Four studies bear on it: a 163-case retrospective reporting resolution in 31 minutes, RAVE-I concluding antivenom may add nothing over placebo, RAVE-II finding no benefit over standardised analgesia in 224 patients, and a 60-patient trial meeting its primary endpoint. Each carries a supports: value pointing the way its own source points, and a discussion lists the four candidate explanations for the disagreement. Calcium gluconate is curated as a refuted former standard with REFUTE evidence and deliberately no target_mechanisms edge. Ontology. Every CURIE was re-derived from a live OLS lookup at the point of writing; none from the research report was used. The report's term validation flagged three that name unrelated concepts (HP:0100751 offered as Excessive salivation is Esophageal neoplasm; HP:0000640 as Dilated pupil is Gaze-evoked nystagmus; HP:0025400 as Priapism is Nodular-random pattern on pulmonary HRCT), plus two obsolete terms. The schema caught two of my own errors during the build: HP:0003394 is Muscle spasm not Muscle cramps, and GO:0070588 is a biological process so cannot sit in molecular_functions. Red-team round before PR. A subagent reviewed with fresh context against dismech-pr-review and found three blocking defects, all verified independently before being acted on and all fixed here. 1. Two notes: blocks cited a sibling Scorpion_Envenomation entry as precedent for the ECTO and NCIT bindings. That entry exists only in unmerged PR #12127, so on this branch the justification pointed at nothing. This is the failure CLAUDE.md describes - a false justification that tells the next reviewer the check was already done - and it was wrapped around ECTO and NCIT searches that had genuinely been run, which is what made it read as verified. Both sentences removed; the one true precedent (Snakebite_Envenoming binds NCIT:C15986) kept. 2. A discussion stated the pore was resolved to 3.1 Angstrom. The cached full text says 3.1 is the prepore (state 1) and 3.7 the pore (state 2). Corrected. 3. PMID:42121922, the paper that fills the transduction gap, was cached twice by this PR and cited zero times, while the entry asserted in four places that the step between receptor engagement and exocytosis was unknown. That claim was stale. The edge moved from INDIRECT_UNKNOWN_INTERMEDIATES to INDIRECT_KNOWN_INTERMEDIATES with the intermediates named, the hypothesis description was rewritten, and the REFUTE item on that node was re-scoped: it excludes a G-protein route to channel formation in HEK293 cells, which is a different claim from the secretion route the node makes, and calling it the strongest evidence against the arm was wrong. Also fixed from that round: a node named Catecholamine-Mediated Myocardial Stress asserting a mechanism no cited source demonstrates, renamed Envenomation-Associated Myocardial Injury; PMID:1967610 cited SUPPORT/DIRECT for vesicle depletion when its own calcium-present control found active recycling and no depletion, now INDIRECT with the control added as a REFUTE item and the calcium-free limitation stated in the node; a Myocarditis description claiming reversibility against a cached source saying such cases can be fatal; two clinical_burden claims with no citation; an unsourced antivenom product-composition claim that may have been backwards, removed rather than guessed; the antivenom death in the entry's own most-cited source, which had been omitted from a treatment framed as a risk-benefit judgement; and eight quote_role or evidence_source values, including two on an NLM-typed Review graded PRIMARY_RESULT. Deliberate omissions, recorded in notes: no module conformance, because neuromuscular_transmission_failure and synaptic_vesicle_cycle both model failure of release and this disease is pathological excess - alpha-latrotoxin is the inverse of botulinum toxin; no local bite-site phenotypes, because no cited source describes them quotably; no insect- or crustacean-specific latrotoxins. Tremor and Agitation were drafted and removed for want of a quotable source. Validation: just validate-disorders passes (schema, terms, references batched), 65/65 snippets verified offline, weighted compliance 86.7%, all 13 phenotypes causally connected, causal graph orphan_targets empty (28 nodes, 27 edges), check-genereviews NO_CHAPTER for both collections. Offline gates green: entity-refs, causal-targets, duplicate-keys, enum-values, qualifier-terms, snippet-length, title-snippets, snippet-grading, reference-titles, environmental-evidence, case-collisions. The cited-identifier set was re-derived from the entry, report and sidecar immediately before deciding on cache pruning; four cache files that looked orphaned resolve to report sources cited by PMC or URL rather than PMID, so nothing was pruned.

Claude Code ▸
Black Widow Spider Envenomation (Latrodectism) — Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 47 citations 2026-09-18T17:07:01.518574

Black Widow Spider Envenomation (Latrodectism) — Comprehensive Research Report

1. Disease Information

Overview. Black widow spider envenomation is an acute toxin-mediated injury syndrome ("latrodectism") caused by the bite of female spiders of the genus Latrodectus (family Theridiidae), which inject a venom whose principal vertebrate-active component, α-latrotoxin, produces massive, irreversible presynaptic neurotransmitter release. It is not a genetic/heritable disease but an acquired toxic-exposure/injury entity, and this fact should be reflected in the KB category: Injury designation and in leaving genetic-risk-factor sections largely empty. The syndrome ranges from mild local reaction to a severe systemic pain/autonomic/neuromuscular crisis; case-fatality is now essentially zero in the modern medical era. "Envenomation is called Latrodectism and the symptoms include diaphoresis, hypertension, muscle cramping, weakness, and severe abdominal and/or back pain; however, cases of death are rare" (Springer Nature reference chapter on Latrodectus venom toxins) [1].

Key identifiers: - ICD-10-CM: T63.31– (Toxic effect of venom of black widow spider), with subcodes T63.311 (accidental), T63.312 (self-harm), T63.313 (assault), T63.314 (undetermined), each carrying encounter suffixes (A/D/S) [2]. - MONDO: MONDO:0800176 is asserted in the task template as the target identifier; independent web confirmation of this exact MONDO term was not retrievable via general search in this session — verify directly against the MONDO release/OLS before binding disease_term.term.id (per dismech's Ontology Term Contract, never bind a CURIE from memory). - MeSH: Spider Bites (MeSH D013057) is the general parent heading under which Latrodectus envenomation literature is indexed; a dedicated "Latrodectism" MeSH heading was not confirmed in this session's searches. - HPO/OMIM/Orphanet: Not applicable — this is an acute exogenous toxic injury, not a rare inherited disease, so OMIM and Orphanet have no dedicated entries. - NCBITaxon (causal organism): Genus Latrodectus Walckenaer, 1805 (Theridiidae). Principal North American species: Latrodectus mactans (southern black widow) and Latrodectus hesperus (western black widow); Latrodectus variolus (northern black widow) also occurs in the U.S. [3][4].

Synonyms/alternative names: Latrodectism; black widow spider bite; Latrodectus envenomation; widow spider envenomation (encompassing redback, katipo, button spider, and other regional common names for congeneric species).

Data provenance: Information is drawn from aggregated clinical case series (e.g., a 163-case review, a >23,000-case National Poison Data System analysis), pharmacology/toxinology primary literature, and point-of-care summaries (StatPearls, UpToDate) rather than individual-patient EHR data.

2. Etiology

Disease causal factor: Direct mechanical injection of Latrodectus venom via chelicerae (fangs) during a bite, almost exclusively by adult female spiders — "Latrodectism is caused exclusively by bites from female black widow spiders, which possess larger venom glands, longer fangs, and bodies up to 20 times larger than males" [5]. This is a mechanistic/toxic (not infectious, not primarily genetic) causal factor.

Risk factors: - Environmental/behavioral (dominant category, since there is no meaningful genetic susceptibility axis for a venom-injection injury): - Contact with spider habitats — firewood piles, garages, sheds, outhouses, gardening equipment, undisturbed clutter, outdoor furniture [5]. - Warm-climate/seasonal exposure — "exposures rise in spring and increase through summer/autumn"; the spiders "thrive in warmer climates" and are present on every continent except Antarctica [5]. - Occupational/recreational exposures: gardening, handling firewood, moving stored items, outdoor labor. - Geographic residence in endemic ranges (southeastern U.S. for L. mactans, western U.S./Canada/Mexico for L. hesperus) [5]. - Host factors modulating severity (not "causal" but modify clinical outcome): - Small body size / pediatric age is a recognized severity modifier — "Children are at risk of increased morbidity due to their small size, which is a critical factor in determining the severity of black widow spider envenomation" [6]. Bite-to-body-mass ratio effectively increases relative venom dose. - Pre-existing cardiovascular disease (hypertension, coronary artery disease) — increases risk of clinically significant sequelae from catecholamine surge (hypertensive crisis, myocardial ischemia); ECG evaluation is specifically recommended in patients with chest pain or known coronary disease [StatPearls, NBK499987]. - Pregnancy — envenomation can mimic or precipitate preeclampsia-like features (hypertension, abdominal pain, proteinuria) [7][8]. - Allergy/atopy history is a contraindication-risk factor specifically for antivenom administration, not for the bite itself. - Genetic risk/protective factors: None established or biologically plausible for the acute toxic injury itself — human genetic variation in latrotoxin receptor genes (neurexins, latrophilins/ADGRL1-3) affecting envenomation severity has not been reported in the human clinical literature retrieved in this session. This should be recorded as an evidence gap, not populated with a spurious binding. - Gene-environment interaction: Not applicable in the conventional sense; the "interaction" here is pharmacological (venom dose vs. body mass/pre-existing organ disease) rather than genomic.

3. Phenotypes

Phenotypes are dominated by acute local injury signs and a systemic pain/autonomic/neuromuscular syndrome. Frequency data below come from a large NPDS-derived case series and from a 163-case clinical review referenced in the StatPearls synthesis and Wikipedia's Latrodectism summary [StatPearls NBK499987; 9].

Local (bite-site) phenotypes

Phenotype Onset Frequency (large series) Suggested HP term
Local pain at bite site Minutes 17.9% (as leading complaint in a large multi-severity cohort); near-universal in envenomated cases HP:0012531 (Pain) / HP:0100710 (Impaired pain sensation — not applicable, this is presence of pain)
Erythema/redness Minutes–hours 28.6% HP:0010783 (Erythema)
Edema/swelling at site Minutes–hours 13.6% HP:0000969 (Edema)
Dermal irritation (generic) Minutes 58.7% HP:0000988 (Skin rash) — use judiciously; better modeled as a Pathophysiology/clinical-sign node than forced to an ill-fitting HP term
Fang marks / central punctum Immediate Variable, often subtle (No dedicated HP term; document as a clinical finding in description)
Localized diaphoresis in a ring around the bite ("target" sweating pattern) Minutes–hours Characteristic/near-pathognomonic when present HP:0000975 (Hyperhidrosis)

Systemic (latrodectism) phenotypes

Phenotype Onset Frequency/severity note Suggested HP term
Diffuse muscle rigidity/cramping/spasm 30–60 min, spreading proximally then generalizing Hallmark systemic feature HP:0003745 (Muscle rigidity) / HP:0003394 (Cramps)
Abdominal pain/rigidity (can mimic acute abdomen) Within an hour 9.7% in large series; classic diagnostic confounder HP:0002027 (Abdominal pain)
Back and chest pain Within hours Common HP:0100749 (Chest pain)
Diaphoresis (generalized or regional/asymmetric) Minutes–hours Common, and its unusual regional patterns (below-knee bilateral, asymmetric) are "almost pathognomonic" [10] HP:0000975 (Hyperhidrosis)
Hypertension Within an hour Common; catecholamine-driven HP:0000822 (Hypertension)
Tachycardia Within an hour Common HP:0001649 (Tachycardia)
Nausea/vomiting Within an hour Common HP:0002018 (Nausea) / HP:0002013 (Vomiting)
Headache, dizziness Hours Common HP:0002315 (Headache)
Sialorrhea/lacrimation Hours Reported HP:0100751 (Excessive salivation)
Mydriasis Hours Reported HP:0000640 (Dilated pupil)
"Facies latrodectismica" — periorbital edema, blepharospasm, grimacing flush Hours Distinctive but rarely described; a described diagnostic gestalt [11] (No single dedicated HP term; consider HP:0000534 Periorbital edema + HP:0000582 Blepharospasm as components)
Priapism Hours (uncommon) Rare, male-specific HP:0025400 (Priapism, if present in current HPO)
Restlessness/anxiety Hours Common HP:0000713 (Restlessness)
Respiratory symptoms (dyspnea, tachypnea) Hours Reported, more common in severe cases HP:0002094 (Dyspnea)
Fever/chills Hours Reported HP:0001945 (Fever)

Laboratory/biochemical phenotypes (uncommon but clinically significant)

  • Leukocytosis, hematuria, elevated liver enzymes (nonspecific) [StatPearls NBK499987].
  • Rhabdomyolysis: elevated creatine kinase, myoglobinuria — reported in rare case series, including a case of coexisting rhabdomyolysis, myocarditis, and arrhythmia [12]. HP candidate: HP:0003201 (Muscle fiber necrosis) is not exact; better modeled biochemically via a Biochemical marker (creatine kinase) than forced into HP.
  • Myocarditis: elevated troponin/cardiac biomarkers, echocardiographic wall-motion abnormality and reduced ejection fraction (one case: EF 42%, pulmonary edema, ST elevation) — reversible in reported cases [13][14][15][16].

Severity/course

A 23,409-case NPDS-style series stratified outcomes as: 65% minor clinical effects, 33.5% moderate effects (longer symptom duration, treatment required), 1.4% major/life-threatening effects [StatPearls NBK499987]. Symptom onset is typically within 30–60 minutes of the bite, and the diffuse systemic pain "spreads contiguously from the bite site" proximally to the trunk and other extremities.

Quality of life impact: Pain can be "incapacitating" and "persist for days" in severe latrodectism [Wikipedia/Latrodectism 9], but per StatPearls, "recovery is usually complete within 24 to 48 hours" and long-term pain or muscle spasms are rare, with most patients expected to make a full recovery.

4. Genetic/Molecular Information

There is no host causal gene for this disease — it is a toxin-injection injury. The molecular information that is disease-relevant instead concerns (a) the venom's toxin genes/proteins and (b) the human/vertebrate receptor genes the toxin acts upon.

Venom toxin components: - α-Latrotoxin (α-LTX): the principal vertebrate-specific neurotoxin, ~130 kDa, that forms tetrameric cation-selective membrane pores. "Highly purified α-latrotoxin from black widow spider venom consists of two polypeptides with molecular weights of 130,000 and 8000 (LMWP)" [17]. Structural work: "Structural basis of α-latrotoxin transition to a cation-selective pore" (PMC11449929) elucidates the pore-forming conformational transition [18]. - Latrodectins (α-LTX-associated low-molecular-weight proteins, LMWPs): ~70-residue, 3-disulfide peptides structurally related to crustacean hyperglycemic hormones (an ecdysozoan neuropeptide hormone family); "purified latrodectin is not toxic in insects and mammals" but "appear to augment the neurotoxicity of latrotoxins, probably by increasing their affinity for the membrane target and reducing vertebrate phyla-specificity" [19][20]. - Other latrotoxin paralogs are phylum-selective: five latroinsectotoxins (α, β, γ, δ, ε-LIT, insect-active) and α-latrocrustatoxin (crustacean-active), reflecting toxin gene family diversification [1]. - Molecular evolution: "Molecular Evolution of α-Latrotoxin, the Exceptionally Potent Vertebrate Neurotoxin in Black Widow Spider Venom" (Mol Biol Evol) documents gene-family diversification underlying phylum specificity [21].

Host (vertebrate) receptor genes bound by α-LTX — these are the molecular targets, not causal disease genes, and are the correct anchors for GO/molecular-function annotation of the pathophysiology nodes: - Neurexin-1α (NRXN1, HGNC gene): Ca²⁺-dependent α-LTX receptor. "α-Latrotoxin binds to two distinct families of neuronal cell-surface receptors: neurexins and CIRL/latrophilins... binding of α-Latrotoxin to neurexin is a Ca²⁺-dependent reaction while its binding to CIRL is Ca²⁺-independent" [22]. In α-neurexin triple-knockout mice, "α-neurexins are not required for synapse formation, but are essential for Ca²⁺-triggered neurotransmitter release... because synaptic Ca²⁺ channel function is markedly reduced" [23] — an important mouse-model mechanistic finding (Nature 2003, "α-Neurexins couple Ca²⁺ channels to synaptic vesicle exocytosis") [24]. - Latrophilin-1 / ADGRL1 (CIRL — Calcium-Independent Receptor for α-Latrotoxin): an adhesion GPCR. "Latrophilin 1 (LPHN1/ADGRL1) is an adhesion G-protein-coupled receptor (GPCR) that serves as the principal receptor for α-latrotoxin (αLTX)... Upon activation, LPHN1 engages the Gαq–phospholipase C pathway to generate inositol 1,4,5-trisphosphate (IP3), triggering Ca²⁺ release from intracellular stores via IP3 receptors" [25][26]. Three paralogs (ADGRL1–3) exist in mammals. - Protein Tyrosine Phosphatase σ (PTPRD/PTPσ) has also been reported in the broader literature as a third latrotoxin-interacting receptor family (not directly confirmed in this session's searches — flag for further verification before binding).

Functional consequence at the molecular/cellular level (for functional_impact_category/modifier framing): α-LTX pore formation is a gain-of-function, non-genetic perturbation of the presynaptic terminal — i.e., this is the textbook case in the dismech schema where modifier: GAIN_OF_FUNCTION (or INCREASED for the downstream calcium influx/neurotransmitter release quantity) applies to a biological_processes/molecular_functions node with no host genetic_context, exactly analogous to the viral-oncoprotein pattern documented in CLAUDE.md (HTLV-1 Tax/NF-κB), because the "gain of function" is imposed on host channels/exocytotic machinery by an exogenous protein rather than by a host mutation.

Epigenetics/chromosomal abnormalities: Not applicable — no evidence in this session's search of any epigenetic or chromosomal dimension to human latrodectism.

5. Environmental Information

Environmental factors (primary etiological category for this entry): - Habitat exposure: firewood stacks, garages, sheds, outhouses, undisturbed storage areas, woodpiles, gardening equipment, outdoor furniture, dense ground cover/shrubbery [pest-control/CDC-adjacent sources, 27]. - Climate/season: warm climates; exposures peak spring through autumn [5]. - Geographic exposure zone: endemic range of North American species (L. mactans southeastern U.S.; L. hesperus western North America; L. variolus northern/eastern U.S.) and, worldwide, other Latrodectus species (redback L. hasselti in Australia, katipo L. katipo in New Zealand, European black widow L. tredecimguttatus, button spiders L. indistinctus/L. geometricus in Africa, etc.) — "Latrodectus is worldwide in its distribution... present on every continent except Antarctica" [1][5][28].

Lifestyle/occupational factors: Gardening, firewood handling, moving stored materials, outdoor manual labor, use of outhouses — behaviors that bring hands/extremities into contact with spider harborage. Personal protective behaviors (gloves, shaking out stored clothing/shoes, long sleeves/pants) are risk-reducing environmental/behavioral factors [27].

Infectious agents: Not applicable — this is a venom-injection injury, not an infectious disease (though secondary wound infection at the bite site is a theoretically possible but rarely reported complication and was not specifically documented in this session's sources).

6. Mechanism / Pathophysiology

Ordered causal chain

  1. A mature female Latrodectus spider bites, injecting venom containing α-latrotoxin (α-LTX) and accessory latrodectin peptides through the chelicerae into subcutaneous tissue → leads to local deposition of toxin near cutaneous sensory/autonomic nerve terminals and dermal microvasculature.
  2. α-LTX binds two families of presynaptic membrane receptors — neurexin-1α (Ca²⁺-dependent binding) and latrophilin-1/ADGRL1 (Ca²⁺-independent binding) — which tether the toxin to the plasma membrane → results in toxin oligomerization into a tetramer at the membrane surface.
  3. The membrane-tethered α-LTX tetramer undergoes a conformational transition and inserts into the presynaptic plasma membrane, forming a cation-selective pore → leads to massive, non-physiological Ca²⁺ (and Na⁺) influx into the presynaptic terminal, largely independent of voltage-gated Ca²⁺ channel gating.
  4. In parallel, latrophilin-1/ADGRL1 engagement (Gαq–phospholipase C–IP3 pathway) triggers IP3-receptor-mediated Ca²⁺ release from intracellular (ER) stores — a second, receptor-signaling-dependent route to elevated cytosolic Ca²⁺, operating even without pore formation → this is a documented parallel/branching mechanism, not solely sequential to the pore.
  5. The resulting sustained, supraphysiological rise in cytosolic Ca²⁺ triggers massive, uncontrolled synaptic vesicle exocytosis at both cholinergic (neuromuscular junction, parasympathetic/sympathetic preganglionic) and adrenergic (postganglionic sympathetic) nerve terminals — this Ca²⁺-triggered release pathway is notably documented to occur "independent of the classical synaptic fusion machinery" in some experimental paradigms, i.e., partially SNARE-independent [29] → leads to depletion-then-exhaustion of vesicular pools and continuous, unregulated neurotransmitter discharge.
  6. Neurotransmitters released include acetylcholine (at neuromuscular junctions and autonomic ganglia), norepinephrine and epinephrine (sympathetic terminals/adrenal medulla), dopamine, and glutamate [StatPearls NBK499987] → leads to, downstream, in a branching fashion:
  7. 6a. Excess acetylcholine at the neuromuscular junction → sustained motor end-plate depolarization → diffuse skeletal muscle fasciculation, rigidity, cramping and spasm, spreading contiguously from the bite site to trunk and other extremities.
  8. 6b. Excess catecholamine release (norepinephrine/epinephrine) → adrenergic autonomic storm → hypertension, tachycardia, diaphoresis (including characteristic localized/asymmetric sweating patterns), mydriasis, piloerection, and — in a minority of cases — hypertensive crisis, acute pulmonary edema, and reversible stress-related myocarditis with regional wall-motion abnormality (documented case: EF 42%, ST elevation, elevated troponin, full recovery) [13-16].
  9. 6c. Autonomic/parasympathetic hyperactivity (excess acetylcholine at autonomic ganglia and lacrimal/salivary glands) → nausea, vomiting, sialorrhea, lacrimation, abdominal rigidity/pain (which can mimic an acute surgical abdomen).
  10. 6d. Sustained muscle contraction/rigidity, when severe → rhabdomyolysis (elevated creatine kinase, myoglobinuria), reported to co-occur with myocarditis and arrhythmia in rare severe cases [12].
  11. Local vascular/inflammatory effects at the bite site (direct membrane pore formation in dermal cells plus autonomic vasomotor effects) → leads to localized erythema, edema, the "target"-pattern localized diaphoresis, and occasionally a distinctive facial sign — "facies latrodectismica": periorbital edema, blepharospasm, lacrimation, and a pained/grimacing flush, thought to reflect a combination of local autonomic and reflex muscular effects on the face and orbit [11].
  12. In the great majority of cases, the toxin is progressively cleared/inactivated, vesicular neurotransmitter stores are replenished, and receptor/channel function normalizes → leads to symptom resolution, typically complete within 24–48 hours (StatPearls), though severe pain can occasionally persist for days.
  13. Where antivenom (equine-derived anti-Latrodectus IgG) is administered, circulating unbound and cell-surface-tethered toxin is neutralized before/soon after pore formation → leads to more rapid symptom resolution in responders, though a large placebo-controlled RCT (RAVE-II, redback spider) found antivenom added to standardized analgesia did not produce a clinically meaningful reduction in pain severity or systemic effects compared to placebo [30][31] — an important caveat for the mechanism-to-treatment-efficacy link, and a HUMAN_MODEL_MISMATCH/efficacy-controversy note worth capturing in discussions.

Detail by category

  • Molecular pathways: Gαq–phospholipase C–IP3–Ca²⁺ signaling (latrophilin/ADGRL1 arm); direct cation pore-mediated Ca²⁺ influx (neurexin-tethered α-LTX tetramer arm). GO candidates: GO:0007186 (G protein-coupled receptor signaling pathway), GO:0048016 (inositol phosphate-mediated signaling), GO:0070588 (calcium ion transmembrane transport), GO:0016079 (synaptic vesicle exocytosis), GO:0007268 (chemical synaptic transmission).
  • Cellular processes: massive regulated exocytosis (GO:0045055 regulated exocytosis), disrupted Ca²⁺ homeostasis (GO:0055074 calcium ion homeostasis), and, in severe cases, myocyte injury/necrosis contributing to rhabdomyolysis.
  • Protein dysfunction: Not a host-protein misfolding disease — rather, exogenous toxin protein (α-LTX) directly forms an aberrant membrane channel (a "gain of novel toxic function" at the protein level, structurally characterized in PMC11449929 [18]).
  • Metabolic changes: Secondary — rhabdomyolysis produces myoglobin/CK elevation and can (in principle, per general rhabdomyolysis pathophysiology) risk downstream renal complications, though acute kidney injury from black widow envenomation is reported as rare ("only one study reported acute kidney failure and rhabdomyolysis from black widow spider bites") [StatPearls NBK499987].
  • Immune involvement: Not part of the toxin mechanism itself; immune/hypersensitivity mechanisms become relevant only for the iatrogenic complication of equine-antivenom administration (Type I hypersensitivity/anaphylaxis; Type III serum sickness, observed for 8–12 days post-antivenom) [32].
  • Tissue damage mechanisms: Direct membrane pore formation (local cytotoxicity at bite site); catecholamine-excess-mediated cardiac stress/microvascular effects (myocarditis); sustained-contraction myocyte injury (rhabdomyolysis).
  • Cell types involved (CL terms): presynaptic neuron terminals generally; motor neuron (CL:0000100), sympathetic neuron (CL:0011103 or similar), cardiac myocyte (CL:0000746) in myocarditis cases, skeletal muscle myocyte (CL:0000188) in rhabdomyolysis.
  • Anatomical/systemic involvement: peripheral nervous system (neuromuscular junction, autonomic ganglia), cardiovascular system (secondary), skeletal muscle (secondary), skin (primary local site).
  • Molecular profiling / advanced omics: No transcriptomic, proteomic, or single-cell human-disease-state profiling literature was identified in this session specific to human latrodectism (unsurprising for an acute self-limited toxic injury); venom-side proteomic/transcriptomic characterization of Latrodectus toxin gene families exists (the Mol Biol Evol α-LTX molecular evolution paper) but is venom biology, not host disease-state omics.

7. Anatomical Structures Affected

  • Organ level:
  • Primary: skin/subcutaneous tissue at bite site (UBERON:0002097 skin of body / UBERON:0000014 zone of skin); peripheral nervous system, specifically the neuromuscular junction and autonomic (sympathetic and parasympathetic) ganglia.
  • Secondary: cardiovascular system (heart — myocarditis, hypertensive crisis; UBERON:0000948 heart); skeletal muscle system generally (UBERON:0001134 skeletal muscle tissue) in rhabdomyolysis; gastrointestinal tract (smooth muscle rigidity causing abdominal pain mimicking acute abdomen); rarely kidney (secondary to rhabdomyolysis-associated AKI).
  • Body systems: nervous system (autonomic + neuromuscular), cardiovascular system, musculoskeletal system, integumentary system.
  • Tissue/cell level: peripheral nerve terminal presynaptic membranes (the primary toxin target); vascular smooth muscle/endothelium (autonomic vasomotor effects); cardiac myocytes (myocarditis); skeletal myocytes (rhabdomyolysis); dermal/epidermal tissue at bite site.
  • Subcellular level (GO Cellular Component): presynaptic active zone/plasma membrane (GO:0048786 presynaptic active zone; GO:0042734 presynaptic membrane), synaptic vesicle (GO:0008021), endoplasmic reticulum (as the Ca²⁺ store mobilized by the IP3 arm, GO:0005783/GO:0032991 ER lumen relevant subcompartment).
  • Localization: Bite site is typically the extremities (upper and lower limbs most common per StatPearls). Systemic spread is bilateral/generalized once latrodectism develops, not classically lateralized, though localized/asymmetric diaphoresis patterns near the bite are a documented diagnostic clue.

8. Temporal Development

  • Onset: Acute, minutes to about one hour after the bite for local signs; systemic latrodectism typically develops within 30–60 minutes and can evolve over several hours. There is no congenital or age-restricted "typical onset age" in the Mendelian-disease sense — onset is tied to the moment of envenomation, at any age, though pediatric bites carry disproportionate severity risk.
  • Progression: Symptoms classically spread contiguously from the bite site proximally to trunk, chest, back, and other extremities over the first hours. Peak severity is typically reached within the first several hours to a day.
  • Disease course pattern: Self-limited and non-progressive beyond the acute phase in the overwhelming majority of cases — "most pain and systemic symptomatology are self-limited," and "recovery is usually complete within 24 to 48 hours" (StatPearls). A minority of cases (documented case reports) show a more protracted or complicated course with cardiac/muscle complications requiring days of monitoring, and severe pain can rarely persist for several days.
  • Remission: Spontaneous resolution is the norm without treatment beyond supportive care; antivenom, where effective, accelerates resolution (typically within ~30 minutes of infusion per some case-series claims), though this is contested by the RAVE-II placebo-controlled trial for redback envenomation, which found no significant benefit of antivenom over standardized analgesia [30][31].
  • Critical period: The first several hours post-bite are the critical window for both symptom escalation and for clinical decision-making regarding antivenom/analgesia; cardiac and rhabdomyolysis complications, when they occur, are generally detected within this early window via ECG/troponin/CK monitoring.

9. Inheritance and Population

  • Inheritance pattern: None — this is an acquired toxic injury, not a heritable disease. No penetrance, expressivity, anticipation, mosaicism, founder effect, or carrier-frequency concepts apply.
  • Epidemiology:
  • Incidence: "Approximately 2,600 Latrodectus-species exposures are reported to the National Poison Data System (NPDS) each year" in the U.S.; a commonly cited complementary figure is "approximately 2,200 people are bitten in the United States by black widows every year" per AAPCC data [33][StatPearls NBK499987].
  • Mortality: extremely low; "no deaths have been recorded due to black widow bites since 1983" in the U.S. [33].
  • Severity distribution (large series, n=23,409): 65% minor, 33.5% moderate, 1.4% major/life-threatening effects [StatPearls NBK499987].
  • Population demographics:
  • Geographic distribution: worldwide except Antarctica, following the cosmopolitan range of the genus Latrodectus, with the brown widow (L. geometricus) having achieved a "nearly cosmopolitan range... a suspected consequence of human transport" [34].
  • U.S. species distribution: L. mactans in southeastern states; L. hesperus from Canada to Mexico in the west; L. variolus in the north/east.
  • Seasonal distribution: spring through autumn peak.
  • Age distribution: all ages bitten, but children and small-body-mass individuals experience disproportionately severe envenomation for a given venom dose.
  • Sex ratio of victims: not specifically reported in retrieved sources (note: the sex-differential of the spider — only females bite clinically significantly — is well established, but human victim sex ratio was not found in this session's searches).

10. Diagnostics

  • Clinical diagnosis is primary. "The diagnosis of black widow envenomation is almost exclusively clinically established; visualizing the bite along with its associated symptoms and obtaining a detailed history will allow accurate diagnosis" [35]. Formal confirmation via spider capture/entomologist identification is described in the literature but is explicitly "not recommended practice" as a routine step (StatPearls).
  • Laboratory tests: Generally nonspecific — CBC (leukocytosis), urinalysis (hematuria), liver enzymes; targeted testing for creatine kinase and myoglobin when rhabdomyolysis is suspected; troponin/cardiac biomarkers and ECG when chest pain or cardiac risk factors are present (StatPearls explicitly recommends this).
  • Imaging/functional tests: Echocardiography when myocarditis is suspected (documented reduced ejection fraction and wall-motion abnormality in case reports) [13-16].
  • Electrophysiology: ECG for suspected cardiac involvement (ST-segment changes reported in myocarditis cases).
  • Genetic testing: Not applicable — no genetic testing role.
  • Differential diagnosis (explicitly enumerated in StatPearls): other arthropod bites/stings (scorpion sting, tarantula bite, brown recluse spider bite), acute abdominal pathology (appendicitis, other surgical abdomen, trauma), acute coronary syndrome, primary myocarditis of other etiology, and other causes of back/chest pain and muscle spasm.
  • Screening: No population screening applicable (acute injury, not a heritable or slowly progressive condition).

11. Outcome/Prognosis

  • Survival/mortality: Prognosis is excellent; U.S. mortality is essentially zero in the modern era (no deaths recorded since 1983) [33]. Historical (pre-antivenom-era) mortality was higher but modern supportive care and antivenom access have effectively eliminated fatal outcomes in most reporting systems.
  • Morbidity/function: "Most patients can, and should, expect a full recovery," with resolution "usually complete within 24 to 48 hours" and long-term pain or muscle spasms being rare (StatPearls). Severe pain can occasionally be "incapacitating" and persist for days in a minority of cases.
  • Complications: Rare but documented — reversible myocarditis (multiple case reports, generally full recovery) [13-16]; rhabdomyolysis, occasionally co-occurring with myocarditis and arrhythmia [12]; rare acute kidney injury secondary to rhabdomyolysis; iatrogenic anaphylaxis or serum sickness from equine antivenom administration [32].
  • Prognostic factors: Body size/age (pediatric risk), pre-existing cardiovascular disease, time to treatment, and possibly venom dose (number of bites, spider size/species).

12. Treatment

  • Supportive/first-line care (all severities): Local wound cleaning, tetanus prophylaxis. Note an important negative finding: "Calcium gluconate and methocarbamol have been shown to be ineffective and are no longer recommended" (StatPearls) — historically standard treatments that current evidence does not support.
  • Mild envenomation (local pain only): Oral analgesics (NCIT:C15986 Pharmacotherapy generic action; oral NSAID/acetaminophen as therapeutic_agent).
  • Moderate–severe envenomation (systemic latrodectism):
  • Opioids for pain control (NCIT:C15986 Pharmacotherapy; therapeutic_agent e.g. CHEBI-bound opioid such as morphine).
  • Benzodiazepines for muscle spasm control (NCIT:C15986 Pharmacotherapy; therapeutic_agent e.g. CHEBI:3373 diazepam or similar) — caution advised when co-administering opioids and benzodiazepines; combined take-home prescribing at discharge specifically not recommended (respiratory depression risk).
  • Antivenom (Antivenin Latrodectus mactans, equine-derived; also redback antivenom in Australia):
  • Treatment term: NCIT — an antivenom/antitoxin-specific NCIT concept should be sought (not confirmed in this session; verify via OAK before binding, e.g., candidate NCIT:C946 Antivenin or similar — do not bind from memory).
  • Indicated, per FDA labeling, for "severe envenomation (eg, seizures, hypertensive crisis, respiratory compromise, or intractable pain), with no allergic contraindications" [32].
  • Efficacy is contested: multiple case series describe rapid, dramatic relief ("usually within 30 minutes of infusion"), and StatPearls states antivenom is "safe and highly effective in most patients," reducing need for additional therapy and admission — but the rigorous placebo-controlled RAVE-II RCT in redback envenomation (n=224) found antivenom added to standardized analgesia "did not significantly improve pain or systemic effects" [30][31]. This divergence between observational/case-series claims and RCT evidence is an important curation point — likely warranting a discussions entry with kind: KNOWLEDGE_GAP or explicit efficacy-controversy framing, and differential evidence grading (DIRECT clinical trial evidence vs. case-series/observational evidence) per the dismech evidence discipline.
  • Adverse effects: anaphylaxis (immediate hypersensitivity — flushing, urticaria, bronchospasm, cardiovascular collapse) and serum sickness (observed 8–12 days post-administration), reflecting its equine origin [32].
  • Investigational/human-antibody approaches: A 2024 Frontiers in Immunology paper reports "Human antibodies neutralizing the alpha-latrotoxin of the European black widow," representing an experimental next-generation, non-equine antivenom approach [36].
  • Surgical/interventional: None routinely indicated (wound care only).
  • Rehabilitative/supportive care: Antiemetics for nausea/vomiting; general supportive monitoring (cardiac monitoring, serial CK/troponin as indicated).
  • Clinical trials: ClinicalTrials.gov NCT00657540, "Black Widow Spider Antivenin for Patients With Systemic Latrodectism" [37] — a relevant NCT identifier for a clinical_trials block.
  • Treatment algorithm: Severity-stratified — mild (local wound care + oral analgesia) → moderate (opioids + benzodiazepines, consider observation) → severe (add antivenom after risk-benefit assessment for allergy; ICU-level monitoring for cardiac/respiratory compromise).
  • Species-specific note: In Australia, redback spider (L. hasselti) antivenom is the analogous product, extensively studied in the RAVE/RAVE-II trials; cross-neutralization studies show redback antivenom can neutralize L. mactans/L. hesperus venom in vitro [38].

13. Prevention

  • Primary prevention (environmental/behavioral, the dominant applicable category for this Injury-category entry):
  • Habitat modification: declutter basements/attics/garages, remove debris/leaf litter/rock piles/dense shrubbery, store firewood elevated and ≥20 feet from the house [27].
  • Personal protective measures: wear gloves when moving stored items, gardening, or handling firewood/rocks; wear long sleeves/pants in wooded areas; shake out shoes, gloves, and hats before use [27].
  • Structural exclusion: seal cracks/crevices around windows, doors, and pipes.
  • Pest control: "Sanitation and exclusion can effectively reduce widow spider populations... avoidance and habitat modification techniques are more effective than applying pesticides" [27].
  • Secondary prevention: Prompt recognition/self-identification of bite and early medical evaluation to catch evolving systemic symptoms; patient education on when to seek care (StatPearls: return precautions for rash, joint/muscle pain, hematuria, adenopathy, respiratory distress post-antivenom).
  • Tertiary prevention: Monitoring protocol for at-risk patients (cardiac evaluation/serial ECG/cardiac markers/echocardiography in patients exposed, per case-report recommendations) to catch and manage rhabdomyolysis/myocarditis before progression.
  • Immunization: No vaccine exists or is in development for latrodectism (venom-injection injuries are not vaccine-preventable in the conventional infectious-disease sense).
  • Genetic/carrier screening: Not applicable.
  • Public health interventions: Pest control programs in endemic/high-exposure occupational settings (agriculture, construction); occupational safety guidance (e.g., a U.S. military public health fact sheet on widow spiders was identified in search results [39]).
  • Prophylaxis: No pre-exposure prophylactic medication exists; prophylactic antivenom is not standard practice.

14. Other Species / Natural Disease

  • Taxonomy of the causal organism: Genus Latrodectus (NCBITaxon — genus-level taxon; e.g., Latrodectus mactans NCBITaxon:6753 region, verify exact TaxID via NCBI Taxonomy before binding). The genus comprises "30 currently recognized species" by some counts (Garb et al. 2004), organized into two well-supported clades: the geometricus clade (L. rhodesiensis + cosmopolitan L. geometricus, brown widow) and the mactans clade (all other species, spanning Africa, Middle East, Iberian Peninsula, Australia, New Zealand, and the Americas) [34].
  • Species commonly implicated in human/animal envenomation worldwide: L. mactans (southern black widow, N. America), L. hesperus (western black widow, N. America), L. variolus (northern black widow, N. America), L. tredecimguttatus (European/Mediterranean black widow), L. hasselti (redback spider, Australia — extensively studied via RAVE trials), L. katipo (katipo, New Zealand, endangered native species), L. geometricus (brown widow, now cosmopolitan), L. indistinctus and other button spiders (southern Africa).
  • Natural disease in animals (this is a genuinely cross-species-susceptible toxin, not a human-specific pathology, and OMIA is not applicable since it is not a heritable animal disease):
  • Differential species susceptibility is a key comparative-biology finding: "Canids have some resistance to black widow spider toxin; however, guinea pigs, cats, and horses are highly susceptible" [40].
  • Cats are exceptionally vulnerable: one cited study found "20 of 22 feline victims died subsequent to black widow envenomation with an average survival time of 115 hours after the bite" [40] — this is a striking veterinary mortality statistic worth capturing in an animal_models/comparative-biology note, as it illustrates both the toxin's cross-mammalian potency and marked species-specific sensitivity differences.
  • Dogs are also affected clinically despite relative resistance; veterinary case literature includes reports specifically on the related brown widow spider (L. geometricus) envenomation in dogs [41].
  • "The primary treatment for black widow spider envenomation [in animals] is the administration of specific antivenin, which provides the most permanent and quickest relief of the envenomation syndrome, usually within 30 minutes of infusion" [40] — mirroring human management.
  • Comparative pathology: The core molecular mechanism (α-LTX pore formation/receptor engagement, massive neurotransmitter release) is conserved across vertebrates, explaining why the venom is broadly mammalian-active; species differences in susceptibility likely reflect differences in receptor expression/density, body-mass-to-venom-dose ratios, and baseline autonomic tone rather than a fundamentally different mechanism.
  • Zoonotic potential: Not applicable — this is a direct envenomation injury, not a transmissible infectious disease; there is no animal-to-human transmission pathway beyond the spider bite itself.

15. Model Organisms

Black widow venom and α-latrotoxin have been central research tools in neuroscience (for probing synaptic vesicle exocytosis mechanisms) more than the disease itself being modeled in genetically engineered organisms — this is an important framing distinction for the KB entry (the mechanism is often studied via receptor-knockout models, not via "black-widow-bite disease models" per se).

  • Mouse models (mammalian, genetic):
  • α-Neurexin triple-knockout mice: demonstrate that α-neurexins are dispensable for synapse formation but essential for Ca²⁺-triggered neurotransmitter release, because "synaptic Ca²⁺ channel function is markedly reduced" in their absence — directly implicating the neurexin receptor arm of the α-LTX mechanism (Missler et al., Nature 2003) [24].
  • Latrophilin-1/ADGRL1 studies at the mouse neuromuscular junction: "Latrophilin-1-Mediated Gαq Signaling, Store-Operated Ca²⁺ Entry, and CaV2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction" (2026, Cells) — a recent mechanistic dissection of the latrophilin/IP3/store-operated-calcium-entry arm using pharmacological and (implicitly) genetic mouse NMJ preparations [42][43].
  • Mouse LD50 toxicology studies: intraperitoneal LD50 for L. hesperus venom = 0.64 mg/kg and for L. mactans (N. American) = 0.26 mg/kg in one study; a separate study found L. mactans tredecimguttatus (European) whole venom LD50 = 0.9 mg/kg, and other reports of 1.39 mg/kg for L. mactans; regional venom variation is also documented (L. dahli LD50 0.99 ± 0.01 mg/kg; L. pallidus LD50 0.62 ± 0.01 mg/kg) [44]. These are useful computational_models/toxicology-model data points, though they characterize venom potency rather than disease phenotype recapitulation per se. Acute mouse envenomation signs include "chill, huddle and trembling, hair fold, shortness of breath, flaccid paralysis, difficulty to open eyes, urinary incontinence and hypothermia" [44] (from an egg-extract toxicity study, illustrative of whole-organism venom bioassay phenotypes).
  • Cell/tissue-level models: cultured neurons, permeabilized chromaffin cells, and PC12 cells have been used extensively (Journal of Neuroscience, EMBO J primary literature) to dissect the Ca²⁺-dependent vs. Ca²⁺-independent (SNARE-independent) exocytotic pathways triggered by α-LTX and its recombinant/mutant forms (e.g., LTXN4C mutant) [29][45][46].
  • Invertebrate models:
  • Drosophila neurexin studies at the neuromuscular junction (PLOS ONE, "Neurexin in Embryonic Drosophila Neuromuscular Junctions") establish invertebrate conservation of neurexin's synaptic role, though this models the receptor biology rather than a whole-organism "latrodectism" phenotype [47].
  • Invertebrate/crustacean-selective latrotoxin paralogs (latroinsectotoxins, latrocrustatoxin) themselves are used as pharmacological tools in invertebrate synaptic physiology, reflecting the toxin family's phylum-restricted activity spectrum.
  • Model limitations: No model fully recapitulates the integrated human clinical syndrome of latrodectism (pain, autonomic storm, rare cardiac/muscle complications) — the mouse/cell models are mechanistic dissections of the receptor–exocytosis pathway (largely CELLULAR/MOLECULAR scale, per dismech's biological_scale/model_scale conventions) rather than organism-level recapitulations of the ORGANISM/TISSUE-scale clinical phenotype (myocarditis, rhabdomyolysis). Any modeled_mechanisms link from these models to a disease-level pathophysiology node describing myocarditis or systemic pain would need to be flagged as an upward extrapolation requiring limitations, per the model-credibility conventions in this KB.
  • Applications: These models have been the primary tool for elucidating fundamental presynaptic exocytosis biology broadly (not limited to spider-bite research), and secondarily validate the receptor-engagement/pore-formation mechanism underlying human latrodectism pathophysiology.

Curation Notes for dismech Entry Population

  1. Verify MONDO:0800176 directly (OLS/MONDO release) before binding disease_term.term.id — not independently confirmed via general web search in this session.
  2. No genetic causal factors exist for this entry; the genetic: section, if populated at all, should describe the venom toxin genes (α-latrotoxin, latrodectins) and the human receptor genes (NRXN1, ADGRL1) as molecular-target annotations on pathophysiology nodes, not as disease-causing genes — this is analogous to how an infectious-disease entry might annotate a pathogen virulence factor, and should not populate Genetic.frequency/case_fractions or inheritance patterns.
  3. The antivenom efficacy controversy (RAVE-II RCT vs. widespread case-series claims of benefit) is a strong candidate for a discussions entry — it is a genuine, citable evidence conflict (DIRECT RCT evidence: SUPPORT for "no meaningful benefit"; multiple case series: SUPPORT for "rapid relief") rather than a simple consensus fact.
  4. Cell-of-origin/pathway framing does not apply (not neoplastic); this entry's pathograph should instead be organized around the toxin-mechanism causal chain in Section 6 above, using environmental[].influences_mechanisms to link the "spider bite exposure" node (bound to an ECTO exposure term if one exists for envenomation, else left as free text with a notes: search record) into the pathophysiology cascade — the TRIGGERS predicate is directly applicable here.
  5. Priapism, facies latrodectismica, and the regional diaphoresis patterns are distinctive enough to warrant individual phenotype nodes with careful preferred_term phrasing, since exact HP term matches are imperfect for several of them.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 24
Resolved 24
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 1
Quoted claims not found in source 0
References weighed for topical relevance 24
On topic 13
Off topic 2

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

  • DOI:10.3390/cells15090821 (1 mention) - Latrophilin-1-Mediated Gαq Signaling, Store-Operated Ca2+ Entry, and CaV2.1 Activation Control Spontaneous Exocytosis at the Mouse Neuromuscular Junction
  • shared terms: via, toxin
  • PMC:PMC11154861 (1 mention) - Essential Role of Latrophilin-1 Adhesion GPCR Nanoclusters in Inhibitory Synapses.
  • shared terms: none

Weighed against this report's own most characteristic terms: bite, spider, widow, pain, latrodectism, black, envenomation, muscle, venom, acute, systemic, disease, latrodectus, rhabdomyolysis, injury, clinical, myocarditis, via, toxin, serie.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 49
Resolved 47
Unresolved (possible confabulation) 0
Obsolete 2
Unverifiable 0
Terms whose name was checked 22
Terms named correctly 15
Terms named as a different term 6
Terms whose name is worth a second look 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0800176 (3 mentions) - the report calls it "if available"; MONDO calls it black widow spider envenomation
  • HP:0100751 (1 mention) - the report calls it "Excessive salivation"; HP calls it Esophageal neoplasm
  • HP:0000640 (1 mention) - the report calls it "Dilated pupil"; HP calls it Gaze-evoked nystagmus
  • HP:0025400 (1 mention) - the report calls it "Priapism, if present in current HPO"; HP calls it Nodular-random pattern on pulmonary HRCT
  • HP:0000713 (1 mention) - the report calls it "Restlessness"; HP calls it Agitation
  • HP:0003201 (1 mention) - the report calls it "Muscle fiber necrosis"; HP calls it Rhabdomyolysis

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

  • GO:0048016 (obsolete inositol phosphate-mediated signaling) (1 mention)
  • CHEBI:3373 (CHEBI_3373) (1 mention) - replaced by CHEBI:28837

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0048016 (1 mention) - the report calls it "inositol phosphate-mediated signaling"; GO calls it obsolete inositol phosphate-mediated signaling, and lists "inositol phosphate-mediated signalling" among its other names